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Appendix: Summary of Evidence Table  





Recommendations  1.1, 1.2 
de Graaff , 
20031 
Ninety-six patients (128 
legs) with clinically 
suspected critical limb 
ischemia 
clinical judgment and 
ankle pressure 
transcutaneous 
oxygen pressure  
and toe blood 
pressure guided 
management 
Unblinded RCT. The 
randomization was 
performed by 
computer and was 
prestratified for the 
presence of diabetes 
mellitus and bilateral 
symptoms of CLI 
No significant difference in terms 
of pain score, number of 
amputations, or death 
Wang, 20162 Noninvasive screening 
tests for the prediction of 
wound healing and the 
risk of amputation in 
diabetic foot ulcers 
Various tests Various tests A systematic review 
and meta-analysis of 
37 observational 
studies 
For the TcPo2 test, the pooled DOR 
was 15.81 (95% confidence 
interval [CI], 3.36-74.45) for 
wound healing and 4.14 (95% CI, 
2.98-5.76) for the risk of 
amputation. ABI was also 
predictive but to a lesser degree of 
the risk of amputations (DOR, 2.89; 
95% CI, 1.65-5.05) but not of 
wound healing (DOR, 1.02; 95% CI, 
0.40-2.64). It was not feasible to 
perform meta-analysis comparing 
the remaining tests. The overall 
quality of evidence was limited by 
the risk of bias and imprecision 
(wide CIs due to small sample size) 
Brownrigg, 
20163 
prognostic markers in the 
prediction of wound 
healing or amputation 
among patients with foot 






Various tests Various tests A systematic review 
and meta-analysis of 
11 observational 
studies on 
9 markers of PAD 
Skin perfusion pressure ≥ 40 
mmHg, toe pressure ≥ 30 mmHg 
(and ≥ 45 mmHg) and 
transcutaneous pressure of oxygen 
≥ 25 mmHg were associated with 
at least a 25% higher chance of 
healing. Ankle pressure < 70 mmHg 
and fluorescein toe slope < 18 units 
each increased the likelihood of 
major amputation by around 25%.  
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302 Nondiabetic CLI 
patients treated by 
endovascular means 
The prognostic value 
of WIfI 
None A retrospective 
unadjusted analysis 
was performed of 
prospectively 
collected data 
The amputation-free survival at 12 
months was 87%, 81%, 81%, and 
62%, in the very low-risk, low-risk, 
moderate risk, and very high-risk 
groups, respectively (P = .106). The 
difference was statistically 
significant between the very low-
risk and high-risk groups (hazard 
ratio, 3.4; 95% confidence interval, 
1.1-10.3; P = .029) 
Ward, 20165 93 Patients who presented 
to a public hospital with 
CLI 
The prognostic value 
of WIfI 
None A retrospective 
adjusted analysis 
On multivariable analysis, 
increasing WIfI amputation score 
(odds ratio [OR] 1.84, 1.0-3.39) 
was associated with increased risk 
of one year major amputation rate 
Darling, 
20176 
596 limbs of patients with 





The prognostic value 
of WIfI 
None A retrospective 
adjusted analysis 
WIfI mean score was predictive in 
the entire cohort (HR, 1.4; 95% CI, 
1.1-1.7), the bypass-only cohort 
(HR, 1.5; 95% CI, 1.1-1.9), and the 
endovascular-only cohort (HR, 1.4; 
95% CI, 1.0-1.8) 
Recommendations  3.4, 3.5, 3.6 
Lijmer,  
19967 
441 Patients with suspected 
PAD 
 
noninvasive tests for 
assessing peripheral 
arterial disease 
None A retrospective 
adjusted analysis 
with blinded readers 
For assessing peripheral arterial 
disease (lesions > or = 50%), 
determining an ABI is justified 
(ROC area 0.95 +/- 0.02). For 
disease localized to the aortoiliac 
segment, performing a single test, 
the femoral PI, is sufficient (ROC 
area 0.80 +/- 0.04). For disease 
including the femoropopliteal and 
infrapopliteal segments, a 
combination of tests is necessary 
Aboyans, 
20088 
510 ambulatory patients 
(37% had diabetes) 







A strong association was found 
between diabetes and high ABI 
(OR, 16.0; P < .001). When ABI 
ranges were compared with TBI 
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and Pk-PT results, those with ABI < 
or =0.90 and ABI > or =1.40 
presented similar patterns of 
abnormalities. Pk-PT or TBI, or 
both, was abnormal in more than 
80% of cases in both ABI < or =0.90 
and > or =1.40 groups. The ABI vs 
TBI relationship appeared linear in 
nondiabetic patients, but had an 
inverted J-shape in diabetic 
patients, suggesting high ABI 
masked leg ischemia. 
Saluan, 
20189 
556 Patients from the 
Cohorte des Patients 
ARTériopathes cohort of 
patients hospitalized for 
peripheral arterial disease. 
Patients with CLI were 
enrolled according to the 
Trans-Atlantic Inter-Society 
Consensus Document on 
Management of Peripheral 
Arterial Disease II definition 
and followed up for at least 
1 year 
Comparison of major 
amputation rate according 
to initial ankle pressure 
(AP), systolic toe pressure 










sampling) and low 
risk for selection bias 
but outcome 
assessment was not 
adjusted or blinded 
AP failed to identify 42% of 
patients with CLI. After 1 year, 27% 
of medical and 17% of surgical 
patients had undergone major 
amputation. The TP <30 mm Hg 
predicted major amputation in the 
whole sample and in the medical 
group (odds ratio [OR] 3.5 [1.7-7.1] 
and OR 5 [2-12.4], respectively), 
but AP did not. The TcPO2 <10 mm 
Hg also predicted major 
amputation (OR 2.3 [1.5-3.5] and 
OR 3.8 [2.1-6.8]). The best 
predictive thresholds to predict 
major amputation were STP <30 
mm Hg and TcPO2 <10 mm Hg. 
None of these methods performed 
before surgery was able to predict 
outcome in the revascularized 
patients 
Recommendations  3.7, 3.8 
Larch, 199710 Fifty patients with 
femoropopliteal obstruction 
were examined immediately 
before planned 




2 readers, cross 
sectional design 
The sensitivity of CDS for detecting 
a hemodynamically relevant 
arterial lesion (stenosis or 
occlusion) was 100% in the 
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posterior tibial artery, 78% in the 
anterior tibial artery, and 92% in 
the peroneal artery 
Visser, 
200011 








risk of bias, adjusted 
analysis 
pooled sensitivity for MR 
angiography (97.5% [95% CI: 
95.7%, 99.3%]) was higher than 
that for duplex US (87.6% [95% CI: 
84.4%, 90.8%]). Pooled 
specificities were similar: 96.2% 
(95% CI: 94.4%, 97.9%) for MR 
angiography and 94.7% (95% CI: 
93.2%, 96.2%) for duplex US 
Adriaensen, 
2004 12 










Further imaging was 
recommended more often after CT 
than after DSA (P = .003). Analysis 
of trends demonstrated increasing 
confidence in CT and stable 
confidence in DSA.  
Collins, 
200713 
Symptomatic lower limb 
peripheral arterial disease 






A systematic review 
and meta-analysis of 
113 observational 
studies of moderate 
quality 
For the detection of stenosis 
greater than 50% in the whole leg, 
MRA (14 studies) had the highest 
diagnostic accuracy, with 
sensitivity ranging from 92 to 
99.5% and specificity from 64 to 
99%. CTA (seven studies) was 
slightly inferior to MRA, with a 
sensitivity ranging from 89 to 99% 
and specificity from 83 to 97%, but 
better than DUS (28 studies), which 
had a sensitivity ranging from 80 to 




33 In-patients with chronic 







operative follow up, 
unblinded 
No differences were noted between 
intraoperative findings and 
arteriography. Two of the three 
differences between DA and CA 
were felt to be clinically significant 
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whereas 9 of the 12 differences 
between MRA and CA were felt to 
be clinically significant. On the 
basis of these data in this series, 
MRA does not yet seem to be able 
to obtain adequate data on 
infrapopliteal segments, at least 
not for this highly selected 
population. When severe tibial 
calcification or very low flow states 
are identified, CA may be necessary 
for patients undergoing DA 
Hingorani, 
200815 
906 patients undergoing 
lower extremity 
revascularization 









risk of bias overall. 
Additional CA imaging was 
required for procedural planning in 
102 patients. The areas not 
visualized well included: iliac (73), 
femoral (26), popliteal (17), and 
infrapopliteal (221). Factors 
associated with increased need to 
obtain CA included: DM (p<.001), 
infrapopliteal calcification 
(p<.001), older age (p = .01) and 
limb threatening ischemia 
(p<.001). 
Met, 200916 957 patients with 
intermittent claudication or 







and meta-analysis of 
20 nonrandomized 
studies of moderate 
quality 
The sensitivity of CTA for detecting 
more than 50% stenosis or 
occlusion was 95% (92%-97%) 
and specificity was 96% (95% CI, 
93%-97%). Computed tomography 
angiography correctly identified 
occlusions in 94% of segments, the 
presence of more than 50% 
stenosis in 87% of segments, and 
absence of significant stenosis in 
96% of segments 
Recommendation  4.1 
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522 patients with chronic 
critical leg ischemia 
Various predictors None Prospective 
observational study 
with linkage to 
census information, 
unblinded 
Besides age > or = 70 years 
(relative risk, RR 1.94; 95% 
confidence interval (CI) 1.37-2.70), 
only a history of stroke (RR 1.82; 
95% CI 1.19-2.79) and major 
amputation (RR 1.90; 95% CI 1.30-
2.80) were significantly associated 
with mortality 
Recommendation  4.2 
Faglia, 
201418 
553 diabetic patients 
admitted because of CLI  





Multivariate analysis confirmed the 
independent role of age, history of 
stroke, renal insufficiency and 
dialysis. Combined treatment with 




739 Patients with 
claudication or critical limb 
ischemia who underwent 
diagnostic or interventional 
lower-extremity 
angiography 
Adhering to all four 
guideline-recommended 
therapies (ASA, statins, ACE 








adjustment. Low risk 
of bias. 
After adjustment for baseline 
covariates, patients adhering to all 
four guideline-recommended 
therapies had decreased MACE 
(HR, 0.64; 95% CI, 0.45 to 0.89), 
MALE (major amputation, 
thrombolysis, or surgical bypass) 
(HR, 0.55; 95% CI, 0.37 to 0.83), 
and mortality (HR, 0.56; 95% CI, 
0.38 to 0.82), compared to patients 
receiving less than four of the 
recommended therapies 





Meta-analysis: 287 studies 
involving 135 000 patients 
in comparisons of 
antiplatelet therapy versus 
control and 77 000 in 
comparisons of different 
antiplatelet regimens 
antiplatelet Control Meta-analysis of 
randomized trials of 
various risk of bias 
Allocation to antiplatelet therapy 
reduced the combined outcome of 
any serious vascular event by 
about one quarter; non-fatal 
myocardial infarction was reduced 
by one third, non-fatal stroke by 
one quarter, and vascular mortality 
by one sixth (with no apparent 
adverse effect on other deaths). 
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Absolute reductions in the risk of 
having a serious vascular event per 
1000 were 36 among patients with 
previous myocardial infarction; 38 
among patients with acute 
myocardial infarction; 36 among 
those with previous stroke or 
transient ischaemic attack; 9 
among those with acute stroke; and 




n,  200921 
Meta-analysis of 6 primary 
prevention trials and 16 





participant data from 
randomized trials at 
varying risk of bias 
-In the primary prevention trials, 
aspirin allocation yielded a 12% 
proportional reduction in serious 
vascular events (0·51% aspirin vs 
0·57% control per year, p=0·0001). 
Aspirin allocation increased major 
gastrointestinal and extracranial 
bleeds (0·10% vs 0·07% per year, 
p<0·0001).  
-In the secondary prevention trials, 
aspirin allocation yielded a greater 
absolute reduction in serious 
vascular events (6·7% vs 8·2% per 
year, p<0.0001), with a non-
significant increase in 
haemorrhagic stroke but 
reductions of about a fifth in total 
stroke (2·08% vs 2·54% per year, 
p=0·002) and in coronary events 
(4·3% vs 5·3% per year, 
p<0·0001).  
-In both primary and secondary 
prevention trials, the proportional 
reductions in the aggregate of all 
serious vascular events seemed 
similar for men and women. 
Recommendation  4.4 
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19,185 patients with 
atherosclerotic vascular 
disease manifested as either 
recent ischemic stroke, 
recent myocardial 
infarction, or symptomatic 
peripheral arterial disease 







international trial at 
low risk of bias 
Patients treated with clopidogrel 
had an annual 5.32% risk of 
ischaemic stroke, myocardial 
infarction, or vascular death 
compared with 5.83% with aspirin 
Hiatt, 201723 13,885 patients with 
symptomatic peripheral 
artery disease, with an 
ankle-brachial index (ABI) of 
0.80 or less or prior 
revascularization of the 
lower limbs 
ticagrelor (90 mg twice 
daily) 
clopidogr




randomized trial at 
low risk of bias 
Patients in both groups had similar 
rates of reduction in cardiovascular 
events (CV death, myocardial 
infarction, ischemic stroke) and 
rates of major bleeding. CV events 
occurred in 740 of 6955 (10.6%) 
patients receiving clopidogrel 
(hazard ratio, 1.02; 95% 
confidence interval [CI], 0.92 to 
1.13; P=0.65), acute limb ischemia 
occurred in 1.7% of the patients 
(hazard ratio, 1.03; 95% CI, 0.79 to 
1.33; P=0.85) and major bleeding 
in 1.6% (hazard ratio, 1.10; 95% CI, 
0.84 to 1.43; P=0.49). 
Recommendation  4.5 
Anand 
201724 
7470 Patients with 
peripheral artery disease 
of the lower extremities 
(previous peripheral 
bypass surgery or 
angioplasty, limb or foot 
amputation, intermittent 
claudication with 
objective evidence of 
peripheral artery disease), 
of the carotid arteries 
(previous carotid artery 
revascularisation or 
asymptomatic carotid 
Oral rivaroxaban (2·5 
mg twice a day) plus 
aspirin (100 mg once 
a day), rivaroxaban 
twice a day (5 mg with 
aspirin placebo once a 
day), or to aspirin 
once a day (100 mg 
and rivaroxaban 
placebo twice a day) 
3 arms Multicenter, blinded 
patients and 
investigators, RCT at 
low risk of bias 
Rivaroxaban plus aspirin compared 
with aspirin alone reduced the 
composite endpoint of 
cardiovascular death, myocardial 
infarction, or stroke (126 [5%] of 
2492 vs 174 [7%] of 2504; hazard 
ratio [HR] 0·72, 95% CI 0·57-0·90, 
p=0·0047), and major adverse limb 
events including major amputation 
(32 [1%] vs 60 [2%]; HR 0·54 95% 
CI 0·35-0·82, p=0·0037). 
Rivaroxaban plus aspirin 
combination increased major 
bleeding compared with the aspirin 
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artery stenosis of at least 
50%), or coronary artery 
disease with an ankle-
brachial index of less than 
0·90 
alone group (77 [3%] of 2492 vs 48 
[2%] of 2504; HR 1·61, 95% CI 
1·12-2·31, p=0·0089), 
Recommendation  4.6 
Anand 
200725 






RCT Treating 1000 patients with 
combination therapy as compared 
with antiplatelet therapy alone for 
3 years would lead to 24 fewer 
cardiovascular events but 28 more 
episodes of life-threatening 
bleeding, a net increase in h 
Recommendation  4.7 
Mills 201126 Meta-analysis of 10 RCTs 
enrolling 41778 patients  




RCTs were at low 
risk of bias 
No difference in mortality or CV 
mortality. High dose reduced 
composite endpoints of  CV 
death+nonfatal MI and the 






20,536 adults (aged 40-80 
years) with coronary 
disease, other occlusive 
arterial disease, or diabetes 
40 mg simvastatin daily Placebo Blinded randomized 
trial 
All-cause mortality was 
significantly reduced (1328 
[12.9%] deaths among 10,269 
allocated simvastatin versus 1507 
[14.7%] among 10,267 allocated 
placebo; p=0.0003), due to a highly 
significant 18% proportional 
reduction in the coronary death 
rate (587 [5.7%] vs 707 [6.9%]; 
p=0.0005), a marginally significant 
reduction in other vascular deaths 
(194 [1.9%] vs 230 [2.2%]; 
p=0.07), and a non-significant 
reduction in non-vascular deaths 
(547 [5.3%] vs 570 [5.6%]; p=0.4) 
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1568 men (aged 35-92 
years) with lower extremity 
arterial disease 
400 mg bezafibrate daily Placebo Double blinded 
randomized trial 
Bezafibrate did not reduce the 
incidence of coronary heart disease 
and stroke (RR 0.96, 95% CI 0.76 to 
1.21). There were 90 and 111 
major coronary events in the active 
and placebo groups respectively 
(0.81, 0.60 to 1.08), of which 64 
and 65 were fatal (0.95, 0.66 to 
1.37) and 26 and 46 non-fatal 
(0.60, 0.36 to 0.99). Beneficial 
effects on non-fatal events were 
greatest in men aged <65 years at 
entry, in whom benefit was also 
seen for all coronary events (0.38, 
0.20 to 0.72). There were no 
significant effects in older men. 
There were 60 strokes in those on 
active treatment and 49 in those on 
placebo (1.34, 0.80 to 2.01). There 
were 204 and 195 deaths from all 
causes in the two groups 
respectively (1.03, 0.83 to 1.26). 
Bezafibrate reduced the severity of 
intermittent claudication for up to 
three years. 
Leng, 200029 7 RCTs (698 patients with 
lower limb artherosclerosis) 
Lipid-lowering therapy  Systematic review of 
7 RCTs at low risk of 
bias 
The follow-up period varied from 
four months to three years. The 
overall quality of the included trials 
was high. The trials were 
heterogeneous in terms of 
inclusion criteria, type of drugs 
used and outcomes measured. 
Lipid-lowering therapy produced a 
marked but non-significant 
reduction in mortality (odds ratio 
0.21, 95% confidence interval 0. 03 
to 1.17), but little change in non-
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fatal events (odds ratio 1.21, 95% 
confidence interval 0.80 to 1.83). In 
two trials there was a significant 
overall reduction in disease 
progression on angiogram (odds 
ratio 0.47, 95% confidence interval 
0.29 to 0.77). The changes in ankle 
brachial pressure index and 
walking distance were 
inconsistent, although trials 
showed a general improvement in 
symptoms that could not be 
combined in a meta-analysis. 
Aung, 200730 18 randomized controlled 
trials (10,049 patients with 
PAD) 
Lipid-lowering therapy  Systematic review of 
18 RCTs 
The pooled results from all eligible 
trials indicated that lipid-lowering 
therapy had no statistically 
significant effect on overall 
mortality (Odds Ratio (OR) 0.86; 
95% Confidence Interval (CI) 0.49 
to 1.50) or on total cardiovascular 
events (OR 0.8; 95% CI 0.59 to 
1.09). However, subgroup analysis 
which excluded PQRST showed 
that lipid-lowering therapy 
significantly reduced the risk of 
total cardiovascular events (OR 
0.74; CI 0.55 to 0.98). This was 
primarily due to a positive effect on 
total coronary events (OR 0.76; 
95% CI 0.67 to 0.87). Greatest 
evidence of effectiveness came 
from the use of simvastatin in 
people with a blood cholesterol >/= 
3.5 mmol/litre (HPS). Pooling of 
the results from several small trials 
on a range of different lipid-
lowering agents indicated an 
 
Global Vascular GuidelinesTM on CLTI: Evidence Tables Page 12 
 





improvement in total walking 
distance (Weighted Mean 
Difference (WMD) 152 m; 95% CI 
32.11 to 271.88) and pain-free 
walking distance (WMD 89.76 m; 
95% CI 30.05 to 149.47) but no 
significant impact on ankle brachial 




509,766 patients (aged 21 to 
84) in the Veterans Affairs 
health care system with 2 or 
more visits for 
atherosclerotic 
cardiovascular disease in 
prior 2 years 
high-intensity statin 
therapy (n=150,928); or 





Retrospective cohort During a mean follow-up of 492 
days, there was a graded 
association between intensity of 
statin therapy and mortality, with 
1-year mortality rates of 4.0% 
(5103 of 126 139) for those 
receiving high-intensity statin 
therapy, 4.8% (9703 of 200 709) 
for those receiving moderate-
intensity statin therapy, 5.7% 
(1632 of 28 765) for those 
receiving low-intensity statin 
therapy, and 6.6% (4868 of 
73 728) for those receiving no 
statin (P < .001). After adjusting for 
the propensity to receive high-
intensity statins, the hazard ratio 
for mortality was 0.91 (95% CI, 
0.88-0.93) for those receiving high- 
vs moderate-intensity statins. The 
magnitude of benefit of high- vs 
moderate-intensity statins was 
similar, for an incident cohort 
hazard ratio of 0.93 (95% CI, 0.85-
1.01). For patients aged 76 to 84 
years, the hazard ratio was 0.91 
(95% CI, 0.87-0.95). Patients 
treated with maximal doses of 
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high-intensity statins had lower 
mortality (hazard ratio, 0.90; 95% 
CI, 0.87-0.94) compared with those 
receiving submaximal doses. 
Recommendation  4.8 
SPRINT, 
201532 
9361 persons with a systolic 
blood pressure of 130 mm 
Hg or higher and an 
increased cardiovascular 
risk, but without diabetes 
systolic blood-pressure 






Randomized trial at 
low risk of bias 
Significantly lower rate of the 
primary composite (CV) outcome 
in the intensive-treatment group 
than in the standard-treatment 
group (1.65% per year vs. 2.19% 
per year; hazard ratio with 
intensive treatment, 0.75; 95% 
confidence interval [CI], 0.64 to 
0.89; P<0.001). All-cause mortality 
was also significantly lower in the 
intensive-treatment group (hazard 
ratio, 0.73; 95% CI, 0.60 to 0.90; 
P=0.003). 
Bavry  201033 2699 PAD patients followed 
for a mean of 2.7 years 
BP target NA  All-cause death, nonfatal 
myocardial infarction, or nonfatal 
stroke occurred least frequently 
among PAD patients treated to an 
average systolic blood pressure of 
135 to 145 mm Hg and an average 
diastolic blood pressure of 60 to 90 
mm Hg. PAD patients displayed a J-
shape relationship with systolic 
blood pressure and the primary 
outcome, although individuals 
without PAD did not. PAD patients 
may require a different target 





4733 participants with type 
2 diabetes 
Intensive therapy, targeting 
a systolic pressure of less 





Low risk of bias, 
precise 
Targeting a systolic blood pressure 
of less than 120 mm Hg, as 
compared with less than 140 mm 
Hg, did not reduce the rate of a 
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composite outcome of fatal and 




The objective of this study 
was to project the potential 
value of adding intensive 
systolic BP goals in high-risk 
patients to the JNC7 or JNC8 
guidelines in a 
contemporary population of 
untreated hypertensive 
individuals aged 35 to 74 
years 
NA NA Simulation and state-
transition (Markov 
cohort) model of 
incidence, 
prevalence, 
mortality, and costs 
of CVD 
Adding intensive systolic blood 
pressure goals for high-risk 
patients prevents an estimated 
43,000 and 35,000 annual CVD 
events incremental to JNC8 and 
JNC7, respectively. Intensive 
strategies save costs in men and 
are cost-effective in women 
compared with JNC8 alone. At a 
willingness-to- pay threshold of 
$50,000 per quality-adjusted life 
years gained, JNC8+intensive had 
the highest probability of cost-
effectiveness in women (82%), and 
JNC7+intensive the highest 
probability of cost-effectiveness in 
men (100%). Assuming higher 
drug and monitoring costs, adding 
intensive goals for high-risk 
patients remained consistently 
cost-effective compared in men, 
but not always in women. 
Recommendation  4.9 
Nathan, 
200536 





Randomized trial at 
low risk of bias 
Intensive treatment reduced the 
risk of any cardiovascular disease 
event by 42 percent (95 percent 
confidence interval, 9 to 63 
percent; P=0.02) and the risk of 
nonfatal myocardial infarction, 
stroke, or death from 
cardiovascular disease by 57 
percent (95 percent confidence 
interval, 12 to 79 percent; P=0.02). 
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7768 patients with type 2 
DM 
Intensive glycemic control Standard 
control 
Randomized trial at 
low risk of bias 
Feasible intensive control of 
diabetes. No significant reduction 
in macrovascular disease but a 
trend toward fewer myocardial 




13 observational studies 
(1,699 patients with type 1 
diabetes, and 7,435 patients 
with type 2 diabetes) 
NA NA Meta-analysis of 13 
prospective cohort 
studies 
The pooled relative risk for 
cardiovascular disease was 1.18; 
this represented a 1-percentage 
point increase in glycosylated 
hemoglobin level (95% CI, 1.10 to 
1.26) in persons with type 2 
diabetes. Results in persons with 
type 1 diabetes were similar but 
had a wider CI (pooled relative 
risk, 1.15 [CI, 0.92 to 1.43]). 
Recommendation  4.10 
Palmer, 
201639 
301 clinical trials (1 417 367 
patient-months) 





trials at overall low 
risk of bias 
Compared with metformin, 
sulfonylurea (standardized mean 
difference [SMD], 0.18 [95% CI, 
0.01 to 0.34]), thiazolidinedione 
(SMD, 0.16 [95% CI, 0.00 to 0.31]), 
DPP-4 inhibitor (SMD, 0.33 [95% 
CI, 0.13 to 0.52]), and α-glucosidase 
inhibitor (SMD, 0.35 [95% CI, 0.12 
to 0.58]) monotherapy were 
associated with higher HbA1C 
levels. Sulfonylurea (odds ratio 
[OR], 3.13 [95% CI, 2.39 to 4.12]; 
risk difference [RD], 10% [95% CI, 
7% to 13%]) and basal insulin (OR, 
17.9 [95% CI, 1.97 to 162]; RD, 
10% [95% CI, 0.08% to 20%]) 
were associated with greatest odds 
of hypoglycemia.  
Recommendation  4.11 
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33 inpatients receiving 
metformin 
Contrast angiography  Retrospective case 
series 
Twenty-nine patients had a normal 
serum creatinine prior to the 
procedure and none had a rise 
following angiography. Four 
patients had an abnormal serum 
creatinine prior to angiography, all 
four patients showed significant 
deterioration and all four patients 
died, two from unrelated causes 




Systematic review of 5 
clinical practice guidelines  
on use of contrast medium 
in patients taking metformin 
Contrast angiography NA NA Recommendations were 
inconsistent regarding need to 
withhold metformin in patients 
with normal vs. abnormal renal 
function. Not all guidelines 
included a specific time period. A 
48 hour withholding period was 
most common recommendation. 
Supporting evidence was of low 
quality, and connection between 
evidence and recommendations 
was unclear. 
Recommendation  4.12 
Blomster, 
201642 
20 countries worldwide 
participating in the 
ADVANCE (Action in 
Diabetes and Vascular 
Disease: Preterax and 
Diamicron modified release 
Controlled Evaluation) trial. 
(6466 never-smokers, 1550 





observation of a trial, 
low risk of bias 
Daily smoking was associated with 
increased risk of major CV events 
and mortality. Men and women had 
similar hazard ratios for most 
subcomponents of outcomes 
Newhall, 
201743 





trial at low risk of 
bias 
Compared to usual care, patients in 
the intervention group were more 
likely to express interest in 
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quitting, acknowledge their 
addictive behaviors,  and when re-
surveyed three months after 
intervention, had larger declines in 




1,600 patients with 
established coronary heart 
disease, mean follow-up 3-




Low risk, RCT Similar relative effects of statins in 
smokers and non smokers 




11,140 patients with type 2 
diabetes aged ≥ 55 years and 
in cardiovascular risk at the 
time of randomisation. 
NA NA Low risk, Cohort Daily smoking was associated with 
increased risk of all primary and 
secondary outcomes with the 




8,905 men and women in 
the Heart Outcomes 
Prevention Evaluation 
(HOPE) trial, with either 
cardiovascular disease, or 
diabetes with at least one 
additional risk factor (2728 
never smokers, 5241 former 
smokers, 936 current 
smokers) 
NA NA Observational cohort Patients were followed for 4.5-
years. Smokers, as compared with 
never smokers had adjusted 
relative risks for cardiovascular 
death of 1.65 [95% confidence 
interval (CI), 1.28-2.14], for 
myocardial infarction of 1.26 (95% 
CI, 1.01-1.58), for stroke of 1.42 
(95% CI, 1.00-2.04), and for total 
mortality of 1.99 (95% CI, 1.63-
2.44).  
Recommendation  4.13 
Kondo, 
201146 
25,464 healthy Japanese 
men, with no known 
diseases and not taking 
medications for 
hypertension, diabetes or 
dyslipidemia 
NA NA Observational cohort Fewer total CVD events were 
observed with an increasing 
duration of quitting, with a 
statistically significant reduction in 














trial without baseline 
assessment 
More patients in the intervention 
group reported “a lot” or “some” 
interest in quitting following their 
initial appointment with the 
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medications and referral to 
quit line  
vascular surgeon (95.4 vs 85.7%, 
p=0.05). At 3-month follow-up, 
37% of those with a strong desire 
to quit were successful, as 
compared with 23% of those with a 
weak desire. 
Recommendations  6.3, 6.4, 6.5 
Schanzer, 
200847 
Patients who underwent 
infrainguinal vein bypass 
surgery for CLI. Two 
datasets were used: the 
PREVENT III randomized 
trial (n = 1404) and a 
multicenter registry (n = 
716) 





collected data. For a 
given risk category, 
the AFS estimate was 
consistent between 
the derivation and 
validation sets 
Stratification of the patients in 3 
risk categories yielded three 
significantly different Kaplan-Meier 
estimates for 1-year AFS (86%, 
73%, and 45% for low, medium, 
and high risk groups, respectively) 
Bradbury, 
201048 
2020 Patients with severe 
lower limb ischemia due to 
infrainguinal disease who 
survived for 2 years after 
intervention (BASIL trial) 




model based on RCT 
at low risk of bias 
evaluating the effect 
of baseline variables 
Baseline factors that were 
significant were BASIL 
randomization stratification group, 
below knee Bollinger angiogram 
score, body mass index, age, 
diabetes, creatinine level, and 
smoking status. The factors that 
contributed to the Weibull 
predictive model were age, 
presence of tissue loss, serum 
creatinine, number of ankle 
pressure measurements detectable, 
maximum ankle pressure 
measured, a history of myocardial 
infarction or angina, a history of 
stroke or transient ischemia attack, 
below knee Bollinger angiogram 




4985 individuals after 
bypass surgery for CLI from 
bypass surgery None Retrospective data 
analysis from a 
Higher model scores were 
significantly associated with higher 
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rates of mortality, all major 
morbidities, and 30-day major 
morbidity and mortality 
Simons, 
201650 
7754 Patients with CLI from 
the national Society for 
Vascular Surgery Vascular 
Quality Initiative database 
bypass surgery None Retrospective data 





Three prediction models had 
similar discriminative 
performance: (BASIL), Finland 
National Vascular (FINNVASC) 
registry, and the modified Project 
of Ex-vivo vein graft Engineering 
via Transfection III (PREVENT III 
[mPIII]). A novel VQI-derived 
model had improved 
discriminative ability with a c-
index of 0.71. 
Biancari, 
200751 







None Retrospective data 







In the validation data set, the 30-
day postoperative 
mortality/amputation rates in 
patients with scores of 0, 1, 2, 3, 
and 4 were 4.8%, 7.5%, 10.1%, 
15.9%, and 22.2%, respectively, (P 
< 0.0001); mortality rates were 
0.7%, 2.3%, 4.2%, 5.5%, and 
14.8%, respectively, (P < 0.0001); 
and major amputation rates were 
4.6%, 5.3%, 6.4%, 11.0%, and 
14.0%, respectively (P = 0.011). 
Recommendation  6.10 
Lavery 
200852 
162 Patients with large, 
chronic, 
nonischemic diabetic foot w
ounds following 
partial foot amputation. 
NA NA Re-analysis of RCT, 
moderate risk of bias 
Early changes in percentage of 
wound area reduction were 




203 patients with diabetic 
foot ulcers 
NA NA Re-analysis of RCT, 
moderate risk of bias 
The percent change in foot ulcer 
area after 4 weeks of observation is 
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250 control group subjects 
from two RCTs of human 
fibroblast-derived dermal 
substitute for treating 
diabetic foot ulcers 
NA NA Re-analysis of data 
from two RCTs  
Regardless of baseline size 
category, DFUs with < 50% 
persistent area of reduction (PAR) 
at 4 weeks were less likely to heal 
by 12 weeks than DFUs with > or = 
50% PAR (P < or = 0.001). 
Sensitivity and specificity was 
higher with cutoff of 4 weeks, than 
weeks 1 to 3.  
Cardinal, 
200855 
241 diabetic foot ulcers from 
patients enrolled in RCTs on 
topic wound treatments 
NA NA Re-analysis of data 
from two RCTs 
Wound margin advance, initial 
healing rate, percent wound 
surface area reduction, and wound 
healing trajectories (all p<0.001) 
were powerful predictors of 
complete wound healing at 12 
weeks. Wounds with poor healing 
progress by these criteria at 4 
weeks were highly likely to remain 
unhealed after 8 additional weeks 
of treatment. 
Recommendation  6.11 
Abu Dabrh, 
201556 
13 studies enrolling 1527 
patients with CLI 
Natural history None Meta-analysis of 
observational studies 
at increased risk of 
bias 
During a median follow-up of 12 
months, all-cause mortality rate 
was 22% (confidence interval [CI], 
12%-33%) and major amputation 
rate was 22% (CI, 2%-42%). 
Worsened wound or ulcer was 
found at 35% (CI, 10%-62%). The 
quality of evidence was low 
because of increased risk of bias 
and inconsistency. 
Recommendations 6.6, 6.12, 6.13, 6.14 
Cull, 201457 139 patients with foot 
wounds who presented for 
NA NA Retrospective 
analysis of 
The WIfI clinical stage was 
predictive of 1-year limb 
amputation (stage 1, 3%; stage 2, 
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10%; stage 3, 23%; stage 4, 40%) 
and wound nonhealing (stage 1, 
8%; stage 2, 10%; stage 3, 23%; 
stage 4, 40%) 







no blinded outcome 
adjudication  
The amputation group had a 
significantly higher prevalence of 
advanced stage 4 patients (P < 
.001), whereas the limb salvage 
group presented predominantly as 
stages 1 to 3. Patients in clinical 
stages 3 and 4 had a significantly 
higher incidence of amputation (P 
< .001), decreased AFS (P < .001), 
and delayed wound healing time (P 
< .002) compared with those in 
stages 1 and 2.  
Darling, 
201559 
596 limbs of patients 
undergoing an infrapopliteal 
angioplasty for CLI 




adjusted analysis, no 
blinded outcome 
adjudication  
One-unit increase in the WIfI 
composite score is associated with 
a decrease in wound healing (HR, 
1.2; 95% CI, 1.1-1.4) and an 
increase in the rate of stenosis (HR, 
1.2; 95% CI, 1.1-1.4) and major 




143 patients hospitalized for 
threatened limb 




data of consecutive 
patients 
Increased WIfI stage was 
associated with major adverse limb 
events (P = .018), reduced limb 
salvage (P = .037), and decreased 
AFS (P = .048). PREVENT III  risk 
score category was associated with 








data of consecutive 
Increasing WIfI stage was 
associated with decreased 1-year 
Kaplan-Meier limb salvage (stage 
1: 96%, stage 2: 84%, stage 3: 90%, 
and stage 4: 78%; P = .003) and 
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51 Patients who had lower 
extremity revascularization  
Real-time imaging of the 
















Preoperative mapping was found 
to be accurate in 50 to 51 patients 
(98%). Vein size as determined by 
B-mode ultrasound correlated well 
with angiograms, R = 0.85 overall 
with R greater than 0.9 in the last 7 
months of the study. Wound 
complications occurred in 2% of 
the patients who had preoperative 




239 infrapopliteal reversed 
greater saphenous vein graft 
bypasses placed for critical 
ischemia over a 7-year 
period 
NA NA Nonrandomized 
prospective cohort 
study, unblinded 
A pattern of increasing graft 
patency and limb salvage was 
noted as the minimum external 
diameter increased from less than 




1404 North American 
patients with critical limb 
ischemia   
lower extremity bypass NA Secondary analysis of  
RCT 
Vein diameter and conduit type 
were the dominant technical 
determinants of early and late graft 
failure. 
Recommendations 6.20, 6.21, 6.22, 6.23, 6.24 
Harward, 
199565 
450 patients undergoing 
lower extremity arterial 
reconstruction 
NA NA Retrospective 
unblinded cohort 
study 
The majority of complications and 
deaths occurred in patients 
undergoing aortic inflow plus 
complex outflow procedures 
(profundaplasty and/or composite 
bypass conduits), in which the 
morbidity/mortality rates were 
84.2% and 47.4%, respectively, 
compared with rates of 45.7% and 
2.9% (p < 0.01) after all 
other inflow/outflow procedures. 
The increased difficulty of these 
 
Global Vascular GuidelinesTM on CLTI: Evidence Tables Page 23 
 





complex procedures is reflected in 
the significantly greater blood loss 
and operative times (1853 mL and 
10.0 hours) compared with similar 
values (1125 mL and 7.7 hours)(p 
< 0.01) for all 





performed during a 6-year 
period 




reconstruction for multilevel 
arterial occlusive disease is a safe 
and effective method of treating 




Meta-analysis of 19 
nonrandomized studies 
(1711 patients) 
Endovascular approach NA Uncontrolled studies Technical success was achieved in 
86% to 100% of the patients. 
Clinical symptoms improved in 
83% to 100%. Mortality was 
described in seven studies and 
ranged from 1.2% to 6.7%. 
Complications were reported in 3% 
to 45% of the patients. Most 
common complications were distal 
embolization, access site 
hematomas, pseudoaneurysms, 
arterial ruptures, and arterial 
dissections. 
Ye, 201168 Meta-analysis of 16 
endovascular treatment 
studies (958 patients) 
Endovascular approach NA Retrospective, 
uncontrolled studies 
Technical success was achieved in 
92.8% of patients (95% confidence 
interval [CI], 89.8%-95.0%, 749 
cases). Primary patency at 12 
months was 88.7% (95% CI, 
85.9%-91.0%, 787 cases). 
Subgroup analyses demonstrated a 
technical success rate of 93.7% 
(95% CI, 88.9%-96.5%) and a 12-
month primary patency rate of 
89.6% (95% CI, 84.8%-93.0%) for 
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TASC C lesions. For TASC D lesions, 
these rates were 90.1% (95% CI, 




120 patients with TASC II A 
& B iliac lesions 
Endovascular treatment  Multicenter 
prospective cohort 
The primary patency rate for the 
total patient population was 97.4%. 
The primary patency rates at 12 
months for the TASC II class A and 
TASC II class B(C) lesions were 
respectively 98.3% and 96.6%. 
Recommendation 6.26 
Indes, 201370 Meta-analysis of 29 open 
bypass studies (3733 
patients) and 28 
endovascular treatment 
studies (1625 patients) in 
aortoiliac occlusive disease 






Mean length of hospital stay (LOS) 
was 13 days for open bypass vs. 4 
days for endovascular treatment 
procedures (p<0.001). The open 
bypass group experienced more 
complications (18.0% vs. 13.4%, 
p<0.001) and greater 30-day 
mortality (2.6% vs. 0.7%, p<0.001). 
At 1, 3, and 5 years, pooled primary 
patency rates were greater in the 
open bypass group vs. the 
endovascular cohort (94.8% vs. 
86.0%, 86.0% vs. 80.0%, 82.7% vs. 
71.4%, respectively; all p<0.001); 
the same was true for secondary 
patency [95.7% vs. 90.0% 
(p=0.002), 91.5 vs. 86.5% 
(p<0.001), and 91.0% vs. 82.5% 
(p<0.001), respectively] 




Systematic review of 
mostly observational 
studies 
Operative mortality rate was 4.1% 
for aortofemoral bypass (AFB), 
2.7% for iliofemoral bypass (IFB), 
and 2.7% for aortoiliac 
endarterectomy (AIE). Systematic 
morbidity rate was 16%, 18.9%, 
and 12.5%. Local morbidity rate 
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was 6.3% for AFB, 5.7% for IFB, 
and 2.4% for AIE. Graft-related 
morbidity/intervention failure 
rates were 3.1%, 4.2%, and 3.8%. 8 
studies reported infection rates 
following AFB, with a combined 
rate of 0.4%. 5-year patency rates 
for patients with CLI were 79.8% 
for AFB and 74.1% for IFB, and 
81.7% for AIE. 
Ricco, 200872 143 patients with unilateral 
iliac artery occlusive disease 
and disabling claudication 
Crossover bypass Direct 
bypass 
 Primary patency at 5 years was 
higher in the direct bypass group 
than in the crossover bypass group 
(92.7 +/- 6.1% vs 73.2 +/- 10%, P = 
.001). Assisted primary patency 
and secondary patency at 5 years 
were also higher after direct 
bypass than crossover bypass (92.7 
+/- 6.1% vs 84.3 +/- 8.5%, P = .04 
and 97.0 +/- 3.0% vs 89.8 +/- 7.1%, 
P = .03, respectively). Patency at 5 
years after crossover bypass was 
significantly higher in patients 
presenting no or low-grade SFA 
stenosis than in patients 
presenting high-grade (> or =50%) 
stenosis or occlusion of the SFA 
(74.0 +/- 12% vs 62.5 +/- 19%, P = 
.04). In both treatment groups, 
patency was comparable using 
polytetrafluoroethylene (PTFE) 
and polyester grafts. Overall 
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Kang, 200873 65 limbs in 58 patients with 
occlusive disease of the 






Technical success was achieved in 
100% of the cases. 1- and 5-year 









There were no perioperative 
deaths or major complications. 7-
year rates of freedom from further 
revascularization and survival 
were 79% and 80%, respectively. 
Recommendation 6.28 
Chang 200875 171 patients (mean age, 67 
+/- 10 years; 38% female; 
35% diabetic) 
CFA endarterectomies and 




Technical success occurred in 98% 
of patients. Clinical improvement 
was seen in 92% of patients. Mean 
ankle-brachial index increased 
from 0.38 +/- 0.32 to 0.72 +/- 0.24. 
Median length of stay was 2 days 
(range, 1-51 days). Thirty-day 
mortality was 2.3% and 5-year 
survival was 60%. Five-year 
primary, primary-assisted, and 
secondary patencies were 60%, 
97%, and 98% respectively. 
Endovascular reintervention was 
required in 14% of patients; inflow 
surgical procedures were required 
in 10%. By logistic regression 
analysis, use of stent grafts 
compared with bare stents was 
associated with significantly higher 
primary patency (87% +/- 5% vs 




98 patients with 
symptomatic obstructions of 
the common femoral artery 
endovascular therapy NA Consecutive series, 
adjusted analysis 
Primary sustained clinical 
improvement rates at 3, 6, 12, and 
24 months were 55%, 55%, 40%, 
and 0% in CLI patients and 81%, 
75%, 68%, and 52% in claudicants, 
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respectively. Limb salvage rates at 
24 months were 94% in CLI 
patients and 100% in claudicants. 
Bonvini, 
201177 
97 patients with 
symptomatic obstructions of 
the common femoral artery 
endovascular therapy NA Prospectively 
maintained single-




Failures-defined as a final 
angiographic result with a >30% 
residual stenosis-were observed on 
26 occasions (7.2%). In-hospital 
major (i.e., requiring surgery) and 
minor (i.e., treated percutaneously 
or conservatively) complications 




117 patients with de novo 
atherosclerotic lesions of the 
CFA 
Stenting Surgery Randomized trial, 
moderate risk of bias 
Primary outcome (mortality and 
complications) occurred in 16 of 61 
patients (26%) in the surgery 
group and 7 of 56 patients (12.5%) 
in the stenting group (odds ratio: 
2.5; 95% confidence interval: 0.9 to 
6.6; p = 0.05). The mean duration 
of hospitalization was significantly 
lower in the stenting group (3.2 ± 
2.9 days vs. 6.3 ± 3 days; p < 
0.0001). At 24 months, the 
sustained clinical improvement, the 
primary patency rate, and the 
target lesion and extremity 
revascularization rates were not 
different in the 2 groups 
Siracuse, 
201679 
1014 patients with PAD isolated CFA intervention 





Survival was 92.9% at 1 year and 
87.2% at 3 years. Amputation-free 
survival, freedom from loss of 
patency or death, and 
reintervention-free survival were 
93.5%, 83%, and 87.5% at 1 year, 
respectively. Multivariable 
predictors of mortality were tissue 
loss, chronic obstructive 
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pulmonary disease, end-stage renal 
disease, urgent case, and age, 
whereas aspirin use and non-
Caucasian race were protective. 
Tissue loss, rest pain, COPD, end-
stage renal disease, stent use, 
nonambulatory status, and female 
sex were predictive of major 
amputation whereas aspirin use, 
P2Y12 antagonist use, statin use, 
and initial technical success were 
protective 
Recommendations 6.32, 6.40, 6.41 
Almasri, 
201780 
44 studies that enrolled 
8,602 patients with chronic 






Prosthetic bypass outcomes were 
notably inferior to vein bypass in 
terms of amputation and patency 
outcomes, especially for below 
knee targets at two years and 
beyond. Drug eluting stents 
demonstrated improved patency 
over bare metal stents in infra-
popliteal arteries (primary 
patency: 73% vs. 50% at 1 year, 
and was at least comparable to 
balloon angioplasty (66% primary 
patency), albeit within an 
anatomically restricted cohort of 
CLTI patients. Survival, major 
amputation and amputation-free 
survival at two years were broadly 
similar between endovascular 
interventions and vein bypass, with 
prosthetic bypass having higher 
rates of limb loss 
Recommendations  6.33, 6.34, 6.35, 6.36, 6.37 
See Abu Dabrh, 2015, Zhan 2015, Darling 2015, Causey 2016, Robinson, 2017 
Recommendation  6.38 
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Chae, 201681 Meta-analysis of 727 
patients with arterial 











at increased risk of 
bias 
Overall limb salvage and wound 
healing rates were significantly 
higher (Odds ratio = 2.209, 3.290, p 
= 0.001, p<0.001) in patients who 
received angiosome-targeted 
angioplasty. The revision rate was 
not significantly different (Odds 
ratio = 0.747, p = 0.314) 
Jongsma 
201782 
Meta-analysis of 19 cohort 
studies with 3932 patients 
with CLI 
Direct revascularization 






studies at low risk of 
bias 
Direct revascularization 
significantly improved wound 
healing (risk ratio [RR], 0.60; 95% 
confidence interval [CI], 0.51-0.71), 
major amputation (RR, 0.56; 95% 
CI, 0.47-0.67), and amputation-free 




Systematic review and meta-
analysis of 9 cohort studies 
(1290 legs)  
Direct revascularization 






at increased risk of 
bias 
The risk of unhealed wound was 
significantly lower after direct 
revascularization (HR 0.64, 95% CI: 
0.52-0.8, I2 0%, four studies 
included) compared with indirect 
revascularization. Direct 
revascularization was also 
associated with significantly lower 
risk of major amputation (HR 0.44, 
95% CI: 0.26-0.75, I2 62%, eight 
studies included). Pooled limb 
salvage rates after direct and 
indirect revascularization were at 1 
year 86.2% vs. 77.8% and at 2 
years 84.9% vs. 70.1%, 
respectively. The analysis of three 
studies reporting only on patients 
with diabetes confirmed the 
benefit of direct revascularization 
in terms of limb salvage (HR 0.48, 
95% CI: 0.31-0.75, I2 0%). 
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Systematic review of 11 case 
series (1616 patients, 1757 
limbs) 
Revascularization  Mostly retrospective 
case series at 
increased risk of bias 
Ten studies compared DR and IR. 
Five studies reported limb salvage 
rate was higher with DR than IR 
(93% vs 72%; P = .02) Five out of 
eight studies who reported wound 
healing rates found a significant 
increase with DR when compared 
with IR; however, length of follow-
up varied among these studies 
(Table I). Mean time to healing was 
not significantly different in DR 
compared with IR when analyzed 
by three studies. One study found a 
significant increase in amputation-
free survival in DR when compared 
with IR (evaluated by three 
studies24, 26, 27). Seven studies, 
with a predominantly diabetic 
population, reported limb salvage 
as a primary outcome, and three 
found a significant increase with 
DR compared with IR. 
Azuma, 
201285 
228 patients (249 limbs) 
with CLTI 
Bypass NA Retrospective 
consecutive case 
series 
The complete healing of ischaemic 
wounds was achieved in 211 limbs 
(84.7%). ESRD (odds ratio (OR) 
0.127, p < 0.001), diabetes (OR 
0.216, p = 0.030), Rutherford 
category 6 (R6) with heel 
ulcer/gangrene (OR 0.134, p < 
0.001), R6 except heel (OR 0.336, p 
= 0.025) and low albuminaemia 
(OR 0.387, p = 0.049) were 
negative predictors of wound 
healing. Regarding the angiosome, 
the healing rate in the indirect 
revascularisation (IR) group was 
slower than in the direct 
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revascularisation (DR) group, 
especially in patients with ESRD (p 
< 0.001). However, the healing 
rates of the DR and IR groups were 
similar after minimising 
background differences with 





44 studies that enrolled 
8,602 patients with chronic 






Prosthetic bypass outcomes were 
notably inferior to vein bypass in 
terms of amputation and patency 
outcomes, especially for below 
knee targets at two years and 
beyond. Drug eluting stents 
demonstrated improved patency 
over bare metal stents in infra-
popliteal arteries (primary 
patency: 73% vs. 50% at 1 year, 
and was at least comparable to 
balloon angioplasty (66% primary 
patency), albeit within an 
anatomically restricted cohort of 
CLTI patients. Survival, major 
amputation and amputation-free 
survival at two years were broadly 
similar between endovascular 
interventions and vein bypass, with 
prosthetic bypass having higher 
rates of limb loss 
Schillinger, 
200686 
104 patients with severe 
claudication or CLTI due to 
stensosi/occlusion of the 
superficial femoral artery 
Stenting angioplas
ty 
RCT Secondary stenting was performed 
in 17 of 53 patients (32 percent) in 
the angioplasty group, in most 
cases because of a suboptimal 
result after angioplasty. At 6 
months, the rate of restenosis on 
angiography was 24 percent in the 
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stent group and 43 percent in the 
angioplasty group (P=0.05); at 12 
months the rates on duplex 
ultrasonography were 37 percent 
and 63 percent, respectively 
(P=0.01). Patients in the stent 
group were able to walk 
significantly farther on a treadmill 
at 6 and 12 months than those in 
the angioplasty group. 
Saxon, 
200887 
197 patients with 
symptomatic PAD of 







Multicenter RCT The stent-graft group had a 
significantly higher technical 
success rate (95% vs 66%, P < 
.0001) and 1-year primary vessel 
patency rate at duplex 
ultrasonography (65% vs 40%, P = 
.0003). A patency benefit was seen 
for lesions at least 3 cm long. At 12 
months, chronic limb ischemia 
status was 15% further improved 
for the stent-graft group (P = .003). 
There were no significant 
differences between treatment 
groups with regard to the 
occurrence of early or late major 
adverse events. 
Dake, 201188 474 patients with 
femoropopliteal PAD (236 
primary drug-eluting stent; 
238 angioplasty) 





Multinational RCT One hundred twenty patients had 
acute PTA failure and underwent 
secondary random assignment to 
provisional DES (n=61) or BMS 
(n=59). Primary end points were 
the 12-month rates of event-free 
survival and patency in the 
primary DES and PTA groups. 
Compared with the PTA group, the 
primary DES group exhibited 
superior 12-month event-free 
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survival (90.4% versus 82.6%; 
P=0.004) and primary patency 
(83.1% versus 32.8%; P<0.001), 
satisfying the primary hypotheses. 
In the secondary evaluations, (1) 
the primary DES group exhibited 
superior clinical benefit compared 
with the PTA group (88.3% versus 
75.8%; P<0.001), (2) the 
provisional DES group exhibited 
superior primary patency (89.9% 
versus 73.0%; P=0.01) and 
superior clinical benefit (90.5% 
and 72.3%, P=0.009) compared 
with the provisional BMS group, 
and (3) the stent fracture rate 




476 patients with 
symptomatic intermittent 
claudication or ischemic 
pain while at rest and 
angiographically significant 
atherosclerotic lesions 







At 12 months, the rate of primary 
patency among patients who had 
undergone angioplasty with the 
drug-coated balloon was superior 
to that among patients who had 
undergone conventional 
angioplasty (65.2% vs. 52.6%, 
P=0.02). The proportion of patients 
free from primary safety events 
was 83.9% with the drug-coated 
balloon and 79.0% with standard 
angioplasty (P=0.005 for 
noninferiority). There were no 
significant between-group 
differences in functional outcomes 
or in the rates of death, 
amputation, thrombosis, or 
reintervention. 
Recommendation  6.42 
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Mills 199290 214 consecutive 
infrainguinal bypass grafts 
(209 reversed-vein and 5 
polytetrafluoroethylene 
grafts) 
duplex ultrasonography NA Prospective 
evaluation of 
consecutive sample, 
unblinded and not 
adjusted 
Thirty-day primary patency was 
99% (129 of 130) for 
femoropopliteal grafts and 93% 
(78 of 84) for femorodistal grafts. 
Secondary patency was 100% (130 
of 130) and 96% (81 of 84), 
respectively. Primary patency was 
89% (16 of 18) for those grafts that 
required intraoperative revision 
based on arteriographic findings. 
Bandyk 
199491 
368 patients after carotid 
endarterectomy, 
infrainguinal vein bypass  or 
visceral/renal 
reconstruction 
duplex ultrasonography NA Uncontrolled and 
nonrandomized 
series 
Duplex scanning identified 
technical (residual plaque, 
stricture) or intrinsic defects 
(platelet thrombus, distal 
thrombosis) requiring revision in 
37 (10%) of the reconstructions. 




Six studies comprising 
nearly 450 patients with 
inoperable chronic critical 
leg ischaemia 




Overall, no significantly different 
effect on ulcer healing was 
observed with the two treatments. 
Complications of SCS treatment 
consisted of implantation problems 
(9%, 95% CI 4 to 15%) and 
changes in stimulation requiring 
re-intervention (15%, 95% CI 10 to 
20%). Infections of the lead or 
pulse generator pocket occurred 
less frequently (3%, 95% CI 0 to 
6%). Overall risk of complications 
with additional SCS treatment was 
17% (95% CI 12 to 22%), 
indicating a number needed to 
harm of 6 (95% CI 5 to 8).Average 
overall costs (one study) at two 
years were EUR 36,500 (SCS 
group) and EUR 28,600 
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(conservative group). The 
difference (EUR 7900) was 




Cochrane review showing 
no trials. Critical lower limb 
ischemia due to non-
reconstructable peripheral 
arterial disease. 
Lumbar sympathectomy Standard 
care 
NA No trials 
Recommendation  7.3 
Abu Dabrh, 
201594 
19 studies enrolling 2779 
patients with CLI 
Medical therapies 
(prostaglandin E1 and 
angiogenic growth factors) 
and devices (pumps and 







studies at increased 
risk of bias 
None of the nonrevascularization-
based treatments were associated 
with a significant effect on 
mortality. Intermittent pneumatic 
compression (OR, 0.14; 95% CI, 
0.04-0.55) and spinal cord 
stimulators (OR, 0.53; 95% CI, 
0.36-0.79) were associated with 
reduced risk of amputation. The 
quality of evidence was low 
because of increased risk of bias 
and imprecision. 
Recommendation  7.4 
Vietto 201895 33 Randomized controlled 





randomized trials at 
increased risk of bias 
Low-quality evidence that suggests 
no clear difference in the incidence 
of cardiovascular mortality 
between patients receiving 
prostanoids and those given 
placebo (risk ratio (RR) 0.81, 95% 
confidence interval (CI) 0.41 to 
1.58).  
High-quality evidence suggests that 
prostanoids have no effect on the 
incidence of total amputations 
when compared with placebo (RR 
0.97, 95% CI 0.86 to 1.09).  
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Adverse events were more 
frequent with prostanoids than 
with placebo (RR 2.11, 95% CI 1.79 
to 2.50; moderate-quality 
evidence) 
Recommendation  7.5 
Smith 201296 8 Trials enrolling 269 
participants 




randomized trials at 
increased risk of bias 
The effect of naftidrofuryl was 
statistically non-significant on pain, 
rest pain, skin necrosis or mean 
ankle systolic pressure 
Recommendation  7.6 
Kranke 
201597 
12 Trials enrolling 269 
participants 
Hyperbaric oxygen therapy Usual 
care 
Meta-analysis of 
randomized trials at 
increased risk of bias 
Increased ulcer healing rate in 
diabetics without significant effect 
on other outcomes. Data 
specifically in CLI were limited  
Game, 201698 Systematic review of 30 
studies, including 13 
hyperbaric oxygen therapy 
trials 
Hyperbaric oxygen therapy  11 RCTs and 2 
retrospective cohort 
studies, at increased 
risk of bias 
Studies have conflicting results. It 
is not yet clear which patients 
would benefit from HBOT. 
Santema, 
201799 
120 patients with diabetes 
with an ischemic wound 
Hyperbaric oxygen therapy Usual 
care 
RCT After 12 months, 28 index wounds 
were healed in the SC group vs. 30 
in the SC+HBOT group (RD 3% 
[95% CI -14 to 21]). AFS was 
achieved in 41 patients in the SC 
group and 49 patients in the 
SC+HBOT group (RD 13% [95% CI 
-2 to 28]). In the SC+HBOT group, 
21 patients (35%) were unable to 
complete the HBOT protocol as 
planned. Those who did had 
significantly fewer major 
amputations and higher AFS (RD 
for AFS 26% [95% CI 10-38]). 
Recommendation  8.1 
Abu Dabrh, 
201594 
19 studies enrolling 2779 
patients with CLI 
Medical therapies 
(prostaglandin E1 and 







None of the nonrevascularization-
based treatments were associated 
with a significant effect on 
 
Global Vascular GuidelinesTM on CLTI: Evidence Tables Page 37 
 





and devices (pumps and 
spinal cord stimulators) 
studies at increased 
risk of bias 
mortality. Intermittent pneumatic 
compression (OR, 0.14; 95% CI, 
0.04-0.55) and spinal cord 
stimulators (OR, 0.53; 95% CI, 
0.36-0.79) were associated with 
reduced risk of amputation. The 
quality of evidence was low 





Meta-analysis of 10 studies 
(499 patients) 




No significant differences were 
observed in major amputation 
rates (relative risk [RR] 0.91; 95% 
confidence interval [CI] 0.65-1.27), 
survival (RR 1.00; 95% CI 0.95-
1.06), and amputation free survival 
(RR 1.03; 95% CI 0.86-1.23) 
between the cell treated and 
placebo treated patients. The ankle 
brachial index (mean difference 
0.11; 95% CI 0.07-0.16), 
transcutaneous oxygen 
measurements (mean difference 
11.88; 95% CI 2.73-21.02), and 
pain score (mean difference -0.72; 
95% CI -1.37 to -0.07) were 
significantly better in the treatment 
group than in the placebo group. 
Recommendation  9.1 
Elsherif 
2017101 
223 diabetic patients who 











The median time to major 
amputation was (400 ± IQR 1205 
days) in the digital amputation 
group, compared to 690 ± IQR 891 
days in the transmetatarsal 
amputation group ( P = 0.974). 
29.9% of digital amputations and 
15.7% of transmetatarsal 
amputations in diabetic patients, 
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required minor amputations or 
revision procedures ( P = 0.04). 
Median length of hospital stay was 
(20 days, IQR 27) in the digital 
group and (17 days, IQR17) in the 
transmetatarsal amputation group 
( P = 0.17). Need for re-admission 
was 48.1% in digital patients 
compared to 50% in 
transmetatarsal amputation 
patients ( P = 0.81). Quality of time 
spent without symptoms of disease 
or toxicity of treatment (Q-TWiST) 
was (315 days, IQR 45) in digital 
group and (346 days, IQR 48) in 
the transmetatarsal amputation 
patients ( P = 0.099) 




undergoing major vascular 
surgery 






matching, no blinding 
Compared with a matched cohort 
of "high-risk" non-DNR patients, 
those with DNR orders suffered 
equivalent rates of postoperative 
morbidity, but markedly increased 
mortality 
Aziz 2015103 16,678 patients underwent 
emergency vascular 
operations 






matching, no blinding 
DNR patients were more likely to 
have higher rates of graft failure 
(8.7% vs 2.4%; adjusted P < .01) 
and failure to wean from 
mechanical ventilation (14.9 % vs 
9.9%; adjusted P < .001). DNR 
status was associated with a 2.5-
fold rise in 30-day mortality 
(35.0% vs 14.0%; 95% confidence 
interval, 1.7-2.9; adjusted P < .001) 
Recommendation  9.3 
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Reed 2008104 33 Patients who had 
undergone below-knee or 
above-knee amputation 
after failed lower extremity 
revascularization 
NA NA Survey with 39% 
nonresponse rate 
Eighty-five percent (28 of 33 
patients) of amputees would do 
everything to save the leg if faced 
with a similar scenario. Fifty-four 
percent (18/33) of patients 
actively used a prosthesis, and 91% 
(30/33) resided at home 





profundaplasties for limb 
salvage 
NA NA Uncontrolled surgical 
case series 
After profundaplasty, ischemic 
ulcers healed in 9 of 17 (53%) 
patients. Rest pain was relieved in 
6 of 19 (32%) and areas of 
ischemic necrosis healed in 7 of 20 
(35%). Cumulative patency of the 
deep femoral artery was 49% at 3 
years but fell to 21% at 5 years, 
whereas cumulative limb salvage 
was 49% and 36%, respectively. 
Eleven of the required 28 
amputations were performed in 
the immediate postoperative 
period. Profundaplasty was used to 
lower the amputation level and 
preserve the knee joint in six 
patients. The other five early 
amputations occurred in severely 
ischemic limbs without distal 
vessels suitable for bypass. The 
profundaplasty remained patent in 
all 19 patients who underwent 
below-knee amputation and 16 




282 profunda femoris artery 
reconstructions 
NA NA Uncontrolled surgical 
case series 
An inflow correction was necessary 
in 60.3% of profunda 
reconstructions. Factors that bear 
on the success or failure of 
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profundaplasty were evaluated. 
These were aorto-iliac inflow, the 
extent of disease in the profunda 
femoris artery, the run-off in the 
distal popliteal-tibial system and 
the extent of the ischemic lesion. Of 
the failures most were due to 
established gangrene, obstructions 
throughout the whole length of the 
profunda or patients with a poor 
popliteal-tibial run-off system. The 
cumulative limb salvage at two 
years was 86.8% in limbs subjected 
to inflow correction procedure and 
profundaplasty but only in 56.5% 
of repair of the profunda alone 
Recommendation  9.5 
Ayoub 
1993107 
32 patients with thru-knee 
amputations for ischemia 
NA NA Uncontrolled 
consecutive surgical 
case series 
Average length of stay was 8.7 
days. One patient required a 
revision to above-the-knee 




309 below-knee amputation 
patients 
NA NA Uncontrolled 
consecutive surgical 
case series 
Patients with coronary artery 
disease [odds ratio (OR), 0.465; 
95% CI, 0.289-0.747], 
cerebrovascular disease (OR, 
0.389; 95% CI, 0.154-0.980), and 
impaired ambulatory ability before 
BKA (OR, 0.310; 95% CI, 0.154-
0.623) were less likely to have a 
successful outcome (wound 
healing, maintenance of 
ambulation and survival for at least 
6 months) with below-knee 
amputation. Patients with impaired 
ambulation combined with another 
factor had only a 20-23% 
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probability of successful outcome 
and patients with all three had a 
10.4% probability of success. 
Recommendation  9.6 
Webster 
2012109 
individuals undergoing their 
first major lower-limb 
amputation because of 
vascular disease and/or 
diabetes 
NA NA Uncontrolled surgical 
case series 
At 4 mo, unsuccessful prosthetic 
fitting was significantly associated 
with depression, prior arterial 
reconstruction, diabetes, and pain 
in the residual limb. At 12 mo, 92% 
of all subjects were fit with a 
prosthetic limb and individuals 
with transfemoral amputation 
were significantly less likely to 
have a prosthesis fit. Age older 
than 55 yr, diagnosis of a major 
depressive episode, and history of 
renal dialysis were associated with 
fewer hours of prosthetic walking 
Recommendation  9.7 
Glaser 
2013110 
1715 Patients undergoing 
lower extremity amputation 
(exclusive of trauma or 
tumor) 
NA NA Uncontrolled surgical 
case series 
Cox proportional hazards 
regression analysis revealed end-
stage renal disease (hazard ratio 
[HR], 3.9; 95% confidence interval 
[CI], 2.3-6.5), chronic renal 
insufficiency (HR, 2.2; 95% CI, 1.5-
3.3), atherosclerosis without 
diabetic neuropathy (HR, 2.9; 95% 
CI, 1.5-5.7), atherosclerosis with 
diabetic neuropathy (HR, 9.1; 95% 
CI, 3.7-22.5), and initial major 
amputation (HR, 1.8; 95% CI, 1.3-
2.6) were independently predictive 




107 vascular amputees 
(mean age 70) referred for 
prosthesis provision 
NA NA Cross sectional study, 
unblinded or 
adjusted 
41% were prescribed a statin and 
39% were prescribed a statin and 
60% an anti-platelet agent. While 
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39% of these patients were on both 
drugs, 32% had been prescribed 
neither 
Recommendations  10.1, 10.2, 10.3, 10.4, 10.5 (also see evidence tables for 4.7, 4.8) 
Bedenis 
2015112 
16 studies with 5683 
randomised participants. 
Nine different treatment 
groups were evaluated: 
aspirin (ASA) or aspirin and 
dipyridamole (ASA/DIP) 
versus placebo or nothing 
(six studies); ASA or 
ASA/DIP versus 
pentoxifylline (two studies); 
ASA/DIP versus indobufen 
(one study); ASA or ASA/DIP 
versus vitamin K antagonists 
(two studies); ASA/DIP 
versus low molecular weight 
heparin (one study); 
ticlopidine versus placebo 
(one study); ASA versus 
prostaglandin E1 (one 
study); ASA versus 
naftidrofuryl (one study); 
and clopidogrel and ASA 






trials at low to 
moderate risk of bias 
Improved graft patency in the ASA 
or ASA/DIP treatment group, odds 
ratio (OR) 0.42 (95% confidence 












not blinded, adjusted 
analysis 
Perioperative mortality (2.6%) and 
major morbidity (3.2%) were not 
different between groups. There 
was no difference in primary 
patency (74% +/- 5% vs 69% +/- 
6%; P =.25), limb salvage (92% +/- 
3% vs 90% +/- 4%; P =.37), or 
survival (69% +/- 5% vs 63% +/- 
5%; P =.20) at 2 years. However, 
 
Global Vascular GuidelinesTM on CLTI: Evidence Tables Page 43 
 





patients on statins had higher 
primary-revised (94% +/- 2% vs 
83% +/- 5%; P <.02) and 
secondary (97% +/- 2% vs 87% 
+/- 4%; P <.02) graft patency rates 
at 2 years. Of all factors studied by 
univariate analysis, only statin use 
was associated with improved 
secondary patency (P =.03) at 2 




293 patients (338 
infrainguinal bypass 
procedures 
NA NA Retrospective case 
series 
Statin drugs were taken by 56% of 
patients, ACE inhibitors by 54% of 
patients, and antiplatelet agents or 
warfarin sodium (Coumadin) by 
93% of patients. Statin drug use 
was independently associated with 
increased graft patency (odds ratio 
[OR], 3.7; 95% confidence interval 
[CI], 2.1-6.4) and with decreased 
amputation rate (OR, 0.34; 95% CI, 
6.15-0.77). Kaplan-Meier analysis 
showed that only ACE inhibitors 
were associated with lower 
mortality (P =.05) 
Suckow, 
2015115 
2067 infrainguinal bypass 
patients, from the Vascular 
Study Group of New England 
registry (67% with CLTI) 




Despite higher comorbidity 
burdens, long-term survival was 
better for patients taking statins in 
crude (risk ratio [RR], 0.7; P < 
.001), adjusted (hazard ratio, 0.7; P 
= .001), and propensity-matched 
analyses (hazard ratio, 0.7; P = .03). 
In subgroup analysis, a survival 
advantage was evident in patients 
on statins with CLI (5-year survival 
rate, 63% vs 54%; log-rank, P = 
.01) but not claudication (5-year 
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survival rate, 84% vs 80%; log-
rank, P = .59). Statin therapy was 
not associated with 1-year rates of 
major amputation (12% vs 11%; P 
= .84) or graft occlusion (20% vs 
18%; P = .58) in CLI patients. 
Perioperative myocardial 
infarction occurred more 
frequently in patients on a statin in 
crude analysis (RR, 2.2; P = .01) but 
not in the matched cohort (RR, 1.9; 
P = .17). 
Brown, 
2008116 
Systematic review of 
randomized and 
nonrandomized studies of 
patients undergoing 
infrainguinal bypass surgery 





Moderate risk of bias 
overall 
The administration of a variety of 
platelet inhibitors resulted in 
improved venous and artificial 
graft patency when compared to no 
treatment. However, analyzing 
patients for graft‐type indicated 
that those patients receiving a 
prosthetic graft were more likely to 
benefit from administration of 
platelet inhibitors than patients 
treated with venous grafts. 
Willigendael, 
2005117 
Meta-analysis of data from 
29 studies 
NA NA Moderate risk of bias 
overall 
The effect of smoking on graft 
patency in the randomized clinical 
trials and other prospective studies 
had a 3.09-fold (2.34 to 4.08; P < 
.00001) increase in graft failure. 
There is a dose-response 
relationship, with decreased 
patency in heavy smokers 
compared with moderate smokers. 
Smoking cessation restores 
patency rates toward the never 
smokers group. 
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Review of systematic 






Moderate risk of bias 
overall 
Cochrane reviews have shown 
benefits of NRT, as well as a small 
but significant benefit from brief 
physician advice compared to no 
advice (odds ratio [OR] 1.69). More 




851 patients undergoing 
unilateral, below-knee 
bypass graft 






The primary efficacy endpoint was 
a composite of index-graft 
occlusion or revascularization, 
above-ankle amputation of the 
affected limb, or death. In the 
overall population, the primary 
endpoint occurred in 149 of 425 
patients in the clopidogrel group vs 
151 of 426 patients in the placebo 
(plus ASA) group (hazard ratio 
[HR], 0.98; 95% confidence interval 
[CI], 0.78-1.23). In a prespecified 
subgroup analysis, the primary 
endpoint was significantly reduced 
by clopidogrel in prosthetic graft 
patients (HR, 0.65; 95% CI, 0.45-
0.95; P = .025) but not in venous 
graft patients (HR, 1.25; 95% CI, 
0.94-1.67, not significant [NS]). A 
significant statistical interaction 
between treatment effect and graft 
type was observed (P(interaction) 
= .008). Although total bleeds were 
more frequent with clopidogrel, 
there was no significant difference 
between the rates of severe 
bleeding in the clopidogrel and 
placebo (plus ASA) groups (2.1% 
vs 1.2%). 
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165 bypasses in patients 
with multiple comorbidities 
(79% CLTI) 
Preoperative aspirin NA Case series Pre- and postoperative aspirin 
usage was associated with 
increased two-year secondary 
prosthetic graft patency over 
control (preoperative: 78% versus 
44%, P < 0.002 and postoperative: 
72% versus 50%, P < 0.01). 
Preoperative aspirin usage was 
associated with an improvement in 
the rate of amputation (odds ratio 
[OR] = 0.44 [95% CI 0.198-0.997]) 




15,603 patients with clinical 
evident cardiovascular 
disease or multiple risk 
factors 








The primary efficacy end point was 
a composite of myocardial 
infarction, stroke, or death from 
cardiovascular causes. The rate of 
the primary efficacy end point was 
6.8 percent with clopidogrel plus 
aspirin and 7.3 percent with 
placebo plus aspirin (relative risk, 
0.93; 95 percent confidence 
interval, 0.83 to 1.05; P=0.22). The 
respective rate of the principal 
secondary efficacy end point, which 
included hospitalizations for 
ischemic events, was 16.7 percent 
and 17.9 percent (relative risk, 
0.92; 95 percent confidence 
interval, 0.86 to 0.995; P=0.04), 
and the rate of severe bleeding was 
1.7 percent and 1.3 percent 
(relative risk, 1.25; 95 percent 
confidence interval, 0.97 to 1.61 
percent; P=0.09). The rate of the 
primary end point among patients 
with multiple risk factors was 6.6 
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percent with clopidogrel and 5.5 
percent with placebo (relative risk, 
1.2; 95 percent confidence interval, 
0.91 to 1.59; P=0.20) and the rate 
of death from cardiovascular 
causes also was higher with 
clopidogrel (3.9 percent vs. 2.2 
percent, P=0.01). In the subgroup 
with clinically evident 
atherothrombosis, the rate was 6.9 
percent with clopidogrel and 7.9 
percent with placebo (relative risk, 
0.88; 95 percent confidence 
interval, 0.77 to 0.998; P=0.046). 
Cassar, 
2005122 










Clopidogrel plus aspirin inhibits 
platelet function more than aspirin 
alone. Platelet function in the 
clopidogrel group was significantly 
suppressed compared with 
baseline at 1 h, 24 h and 30 days 
after endovascular intervention 
(stimulated fibrinogen binding by 
53.9, 51.7 and 57.2 per cent 




80 patients with peripheral 
artery disease 
endovascularly treated  
pre- and postinterventional 





Blinded trial at low 
risk of bias  
At 6 months, clopidogrel patients 
had significantly lower rates of 
target lesion revascularization  
compared to placebo patients [2 
(5%) vs. 8 (20%), p=0.04]. After 
stopping clopidogrel/placebo after 
6 months, there was no significant 
difference in target lesion 
revascularization  at 12 months 
after treatment [9 (25%) 
clopidogrel vs. 12 (32.4%) placebo, 
p=0.35]. Mortality was 0 vs. 1 in the 
placebo group at 6 months 
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(p=0.32) and 0 vs. 3 at 12 months 
(p=0.08). 
Dual antiplatetet therapy reduces 
peri-interventional platelet 
activation and improves functional 





132 Patients after lower 
limb angioplasty 
clopidogrel and aspirin  placebo 
and 
aspirin, 
Blinded trial at low 
risk of bias  
clopidogrel and aspirin inhibited 
platelet function more than aspirin 
alone in patients with claudication 
before and after angioplasty. 
Recommendation  10.10 
Mills 2001125 156 autogenous 




NA Uncontrolled or 
blinded 
The incidence of graft thrombosis 
was 3% per year (mean follow-up, 
27.5 months). Intermediate lesions 
developed in 32 grafts (20%). 
Among these 32 grafts with 
intermediate stenoses, 63% 
progressed to critical and were 
revised, and 32% resolved or 
stabilized 
Recommendation  10.11 
Landry 
2002126 
330 surgical graft revisions 
were performed on 259 






The assisted primary patency rate 
of all grafts, the limb-salvage rate 
for patients undergoing surgery for 
limb-salvage indications, and the 
survival rate of all patients were 
87.4%, 88.7%, and 72.4%, 
respectively, 5 years after the 
original bypass grafting procedure, 
85.7%, 83.4%, and 67.8%, 
respectively, 7 years after the 
original bypass grafting procedure, 
and 80.4%, 75.4%, and 53.4%, 
respectively, 10 years after the 
original bypassgrafting procedure. 
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A total of 180 revisions (55%) 
were performed during the first 
year, 110 (33%) between the first 
year and the fifth year, and 40 
revisions (12%) were performed 
on grafts older than 5 years. 
LEVGs revised within the first year 
after bypass grafting had lesions 
within the graft in 78%, in the 
native arterial inflow in 10%, and 
in the native arterial outflow in 
12%. This differed significantly 
from the location of lesions in 
revisions performed between 1 and 
5 years and after 5 years (graft, 
63% and 62%; inflow, 20% and 




188 vein grafts, from a total 
series of 1260 bypasses, 
undergoing revision of 
stenotic lesions 
Revision procedures 
performed for repair of 
stenotic lesions in 





There was no difference in patency 
rate for different revision 
procedures, type of vein graft, 
indication for the original 
procedure, or for patients with 
diabetes mellitus or renal disease. 
The overall limb salvage rate was 
83.2% +/- 3.5% 5 years after graft 
revision. With COX proportional 
hazard analysis of time to failure of 
the revision procedure, the outflow 
level of the original bypass and the 
time of revision proved to be an 
important predictor of durability of 
the graft revision. Revision of 
popliteal bypass grafts resulted in a 
60% 5-year primary patency rate, 
whereas revision of tibial grafts 
resulted in a 42% 5-year primary 
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patency rate (P = .004; hazard ratio 
[HR], 2.06). Five-year secondary 
patency rates were 90% and 76%, 
respectively (P = .009; HR = 3.43). 
The timing of the graft revision 
proved an additional predictor. 
Grafts revised within 6 months of 
the index operation had lower 
primary patency than those with 
later revisions (42.9% vs 80.7%, 
respectively; HR = 1.754; P = 
.0152) 
Recommendation  10.12 
Bui 2012128 Ninety-four limbs (85 
patients) underwent EVT for 
SFA-popliteal disease 




The initial scans were normal in 61 
limbs (65%), and serial DU results 
remained normal in 38 (62%). In 
17 limbs (28%), progressive 
stenoses were detected during 
surveillance. The rate of 
thrombosis in this subgroup was 
10%. Moderate stenoses were 
detected in 28 (30%) limbs at 
initial scans; of these, 39% 
resolved or stabilized, 47% 
progressed to severe, and 
occlusions developed in 14%. Five 
(5%) limbs harbored severe 
stenoses on initial scans, and 80% 
of lesions resolved or stabilized. 
Progression to occlusion occurred 
in one limb (20%). The last DUS 
showed 25 limbs harbored severe 
stenoses; of these, 13 (52%) were 
in symptomatic patients and thus 
required reintervention regardless 
of DU findings. Eleven limbs (11%) 
eventually occluded. Sensitivity 
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and specificity of DUS to predict 
occlusion were 88% and 60%, 
respectively 




interventions for CLI in 113 
patients (53% male; mean 
age 71 years 







Fifty patients had an abnormal 
early duplex and 40 patients had a 
normal duplex. In patients with a 
normal duplex ultrasound the 
amputation rate was 5% vs 20% in 
the group with an abnormal duplex 
(P = .04). Primary patency was 
56% in the normal duplex group 
and 46% in the abnormal duplex 
group (P = .18). Early duplex 
ultrasound was able to identify a 
residual stenosis not seen on 
completion angiography in 56% of 
cases. 
Recommendations  10.14, 10.15 
Elraiyah 
2016130 
19 interventional studies, of 
which 13 were randomized 
controlled trials, including 
data from 1605 patients 
with diabetic foot ulcers 
using an off-loading method 
Offloading approaches Usual 
care 
The risk of bias in the 
included studies was 
moderate. 
This analysis demonstrated 
improved wound healing with total 
contact casting over removable 
cast walker, therapeutic shoes, and 
conventional therapy. There was 
no advantage of irremovable cast 
walkers over total contact casting. 
There was improved healing with 
half-shoe compared with 
conventional wound care. 
Therapeutic shoes and insoles 
reduced relapse rate in comparison 
with regular footwear. Data were 
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Global Vascular Guideline on the Management of Chronic Limb Threatening Ischemia 
 










Ulcer Gangrene Ischemia Infection Key features and comments 
Ischemia/PAD 
Classifications 
            
Fontaine (1954)  
Yes (Class 
III/IV) 
Class IV/IV - ulcer 
and gangrene 
grouped together 
Class IV/IV - ulcer 
and gangrene 
grouped together 
Cutoff values for CLI  based 
on European consensus 
document:                                             
Ischemic rest  pain > 2 weeks 
with AP < 50 mm Hg or TP 
< 30 mmHg  Ulcer and 
gangrene: AP < 50 mm Hg, 
TP < 30 mm Hg, absent 
pedal pulses in patient with 
diabetes 
No 
Pure ischemia model                                                             
No clear definitions of 
spectrum of hemodynamics; 
minimal  description of 






Category 5 - minor 
tissue loss - 
nonhealing ulcer, 
focal gangrene with 
diffuse pedal 
ischemia 
Category 6 - major 
tissue loss extending 
above TM level, 
functional foot no 
longer salvageable 
(although in practice 






Yes -  cutoffs for "CLI"                                              
Category 4: Resting AP < 40 
mm Hg; flat or barely 
pulsatile ankle or forefoot  
PVR; TP < 30 mmHg                  
Category 5/6: AP < 60 
mmHg;  flat or barely 
pulsatile  ankle or forefoot 
PVR; TP < 40 mmHg 
No 
Pure ischemia model                                                          
PAD classification system 
includes milder forms of PAD 
(Categories 1-3). Categories 4-
6 based on cutoff values for 
CLI; no spectrum of ischemia, 
doesn't acknowledge potential 
need for revascularization with 
< CLI cutoff depending on 
wound extent/infection; not 
intended for patients with 
diabetes; wound classes not 
sufficiently detailed; omits 










and/or TP  
≤30 mmHg 
yes, if  AP ≤50 
mmHg and/or TP  
≤30 mmHg 
yes, if AP ≤50 
mmHg and/or TP  
≤30 mmHg 
One hemodynamic cutoff for 
ulcer and gangrene, with or 
without diabetes 
No 
Ischemia threshold too low, 
especially for patients with 
diabetes; wounds not graded; 
infection not considered 
 
 




yes, if ischemia 
criteria met 
yes, if ischemia 
criteria met 
One hemodynamic cutoff, 
with no differentiation of 
diabetics from non-diabetics 
No 
Focused primarily on 
arteriographic anatomy 
without detailed stratification 
of the limb itself (wounds and 
infection not graded) 
TASC 2 (2007) 
yes, if AP < 
50 mm Hg 
or TP < 30 
mm HG 
yes, if ischemia 
criteria met of AP < 
70 mmHg or TP < 
50 mmHg 
yes, if ischemia 
criteria met of AP < 
70 mmHg or TP < 
50 mmHg 
Yes, but noted "there is not 
complete consensus 
regarding the vascular 
haemodynamic parameters 
required to make the 
diagnosis of CLI" 
No 
Focused primarily on 
arteriographic anatomy 
without detailed stratification 
of the limb itself (wounds and 
infection not graded); issues 










Grade 0: pre- or 
postulcerative lesion          
Grade 1: partial/full 
thickness ulcer   
Grade 2: probing to 
tendon or capsule                                             
Grade 3: deep ulcer 
with osteitis      
Grade 4: partial foot 
gangrene          
Grade 5: whole foot 
gangrene 
Ulcer and gangrene 
grouped together; 
gangrene due to 
infection not 
differentiated from 












intended for Diabetic Feet                                            
No hemodynamics; Gangrene 
from infection not 
differentiated from that due to 
ischemia; Osteomyelitis 
included; soft tissue infection 
not separated from bone 
infection 
University of 
Texas - UT 
(1998)  
No 
Yes: Grades 0 - III 
ulcers                                
Grade 0: pre or 
postulcerative 
completely 
epithelialized lesion                              
Grade I: superficial, 
not involving 
tendon, capsue or 
bone                                     
Grade II: 
penetrating to 
tendon/caspsule                                                 
No 
Yes : Binary +/-                                           
based on ABI < 0.8 













Primarily intended fors DFUs; 
includes validated ulcer 
categories; PAD and infection 
included, but only  as +/- 












                                                                                                                                                                                                                                                                                                   
No 
Yes 0-3 based on 
area and depth                      
Grade 0 skin intact                                 
Grade 1 superficial, 




capsule, 1-3 cm2       
Grade 3 Lesions in 
bone or joint space, 
> 3cm2 
No 
Pulse palpation only, no 
objective hemodynamic 
testing 
  Yes                                                       
1 = no 
infection
2 = cellulitis                                       
3 = 
osteomyelitis 
Intended for DFUs; also
includes neuropathy; does not 
mention gangrene; no
hemodynamic information, 
perfusion assessment based on 
pulse palpation only 
PEDIS (2004) No 
Yes- Grades 1-3                                               
Grade 1: superficial 
full-thickness ulcer, 
not penetrating 
deeper than the 
dermis                                       
Grade 2: deep ulcer, 
penetrating below 
the dermis to 
subcutaneous 
structures involving 
fascia, muscle or 
tendon                                             
Grade 3: All 
subsequent layers of 
the foot involved 
including bone 
No 
Yes: 3 grades, "CLI" cutoff                               
Grade 1: no PAD symptoms, 
ABI>0.9, TBI > 0.6, TcpO2 
> 60 mm Hg                                                   
Grade 2: PAD symptoms, 
ABI <0.9, AP > 50 mmHg, 
TP>30 mmHg, TcpO2 30-60 
mmHg                                         
Grade 3: AP<50 mmHg, 
TP<30 mmHg, TcpO2<30 
mmHg 
Yes Grades 




Primarily intended for DFUs; 
ulcer grades validated;  
includes perfusion assessment, 
but with cutoff for "CLI"; 
gangrene not separately 
categorized; includes validated 









Yes Grades 1-3 
based on depth         
Grade 1: superficial 
wound disrupting 
entire skin                                              
Grade 2: Moderate 
or partial depth, 
down to fascia, 
tendon or muscle 
but not bone or 
joints                                        
Grade 3: Severe or 
total, wounds with 
bone or joint 
involvment                 
Multiple categories 




             Yes                Grades 
0-3                                             
Grade 0: AP > 80 mmHg, 
ABI 0.9-1.2                                                 
Grade 1: AP 70-80 
mmHg,ABI 0.7-0.89, TP 55-
80 mmHg                              
Grade 2: AP 55-69 mmHg, 
ABI 0.5-0.69, TP 30-54  
mmHg                              
Grade 3:  AP < 55 mmHg, 
ABI < 0.5, TP < 30 mmHg 
         Yes         
Grades 0-3                         
Grade 0: 








purulence                         
Grade 2: 
Moderate. 












Detailed system intended only 
for DFUs; comprehensive 
ulcer classification system with 
hemodynamic categories for 
gradations of ischemia; 
gangrene not considered 
separately Infection system 
similar to IDSA  
 
 
IDSA (2012) No No No No 
Yes                                     
Uninfected,                                
Mild, 
Moderate 
and Severe                    
Validated system for risk of 
amputation related to foot 
infection, but not designed to 
address wound 


















                 Yes         
Grades 0-3                                 
Grouped by depth, 
location and size 
and magnitude of 
ablative/wound 
coverage procedure 
required to achieve 
healing 
          Yes           
Grades 0-3                     
Grouped by extent, 
location and size 
and magnitude of 
ablative or wound 
coverage procedure 
required to achieve 
healing 
    Yes   Ischemia Grades 0-3  
hemodynamics with 
spectrum of perfusion 
abnormalities; no cutoff 
value for "CLI". Grade 0 
unlikely to require 
revascularization 







Includes PAD +/- diabetes 
with a range of wounds, 
ischemia  and infection, scaled 
from 0-3. No single cutoff for 
"CLI", as CLTI is considered 
as a spectrum of disease. Need 
for revascularization depends 
on degree of ischemia, wound 
and/or infection severity 
Ulcers/gangrene categorized 
based on extent and 
complexity of anticipated 
ablative surgery/ coverage  
       
ABBREVIATIO
NS 
AP = ankle 
pressure                                        
ABI= ankle-
brachial 
index;                                
TP = toe 








pressure   
mm Hg = 
CLI = Critical Limb 
Ischemia;        
PAD = peripheral 
artery disease;            
DFU = Diabetic 
Foot Ulcer 
UT = University of 
Texas                        
IDSA = Infectious 
Disease Society of 
America                                                       
SVS = Society for 
Vascular Surgery        
WIfI = Wound, 
Ischemia, foot 
Infection 










Table 1.2 One-year major limb amputation rate by SVS WIfI clinical stage 
 
a Number of limbs at risk in each WIfI Stage, with percent of amputations at 1 year in parentheses 
b Means in totals (in parentheses) are weighted 
c *= falsely elevated due to inadvertent inclusion of Stage 5 (unsalvageable) limbs 
  
Study (year): # limbs at risk Stage 1 Stage 2 Stage 3 Stage 4 
Cull (2014)68 : 151 37 (3%) 63 (10%) 43 (23%) 8 (40%) 
Zhan (2015)69: 201  39 (0%) 50 (0%) 53 (8%) 59 (64%)* 
Darling (2016)71: 551  5 (0%) 110(10%) 222 (11%) 213 (24%) 
Causey (2016)70: 160  21 (0%) 48 (8%) 42 (5%) 49 (20%) 
Beropoulis (2016)163: 126  29 (13%) 42 (19%) 29 (19%) 26 (38%) 
Ward (2016)166: 98  5 (0%) 21 (14%) 14 (21%) 58 (34%) 
Darling (2017)164: 992 12 (0%) 293 (4%) 249 (4%) 438 (21%) 
Robinson (2017)72: 280 48 (2.1%) 67 (7.5%) 64 (7.8%) 83 (17%) 
Mathioudakis (2017)165: 217 95 (4%) 33 (3%) 87 (5%) 64 (6%) 
Tokuda (2018)167: 163 16 (0%) 30 (10%) 56 (10.7%) 61 (34.4%) 
N = 2982 (weighted mean in %) 307 (3.2%) 757 (7.0%) 859 (8.7%) 1059 (23.3%) 
Median (% 1-year major limb 
amputation) 


















Figure 2.3. Association of risk factors with the level of atherosclerotic target lesions. Red 
overlay on the anatomic cartoon illustrates the association of risk factor with patterns of 










Figure 3.2. Suggested algorithm for anatomic imaging in patients with CLTI who are candidates 
for revascularization. In some cases it may be appropriate to proceed directly to angiographic 




Table 3.1. Comparison of methods of non-invasive testing in patients with CLTI 
TECHNIQUES ADVANTAGES LIMITATIONS 
Ankle pressure/ABI • Simple, inexpensive, quick, 
widely applicable 
• Provides data to predict wound 
healing and limb survival. 
• Useful to monitor efficacy of 
therapeutic intervention 
• Due to incompressible tibial 
arteries, may be falsely elevated or 
normal in patients with diabetes, 
renal insufficiency, or advanced 
age. 
• Does not provide localization of 
the disease 
Toe pressure/TBI • Simple, inexpensive, quick 
• Useful in the presence of small 
vessel artery disease. 
• Useful in non-compressible 
tibial arteries 
• Provides data to predict wound 
healing and limb survival. 
• Useful to monitor efficacy of 
therapeutic intervention 
 
• Requires a hallux 
• Does not provide localization 
 
Segmental pressures • Useful in initial anatomical 
localization of CLTI disease. 
• Useful in creating therapeutic 
plan based on disease 
localization. 
• Provides data to predict wound 
healing and limb survival. 
• Useful to monitor efficacy of 
therapeutic intervention 
 
• Not accurate in non-compressible 
tibial arteries. 
 
TcPO2 • Useful to assess 
microcirculation 
• Can predict wound healing 
• Maybe useful for monitoring 
efficacy of revascularization 
 
• Limited accuracy in the presence 
of edema or infection 
• Requires skin heating to ≥40°C 
• Time-consuming 
• Limited data validation 
Skin perfusion pressure • Useful to assess 
microcirculation and wound 
healing potential 
• Maybe useful for monitoring 
efficacy of revascularization 
• Can be measured in a shorter 
time compared with TcPO2 
 
• Probe size and shape may affect 
measurements 
• Limited data validation 
TcPO2 = Transcutaneous oximetry. Adapted from Hirsch et al. ACC/AHA 2005 practice guidelines for the 






Table 3.2. Wound grading in WIfI 
Grade Ulcer Gangrene 
0 No ulcer No gangrene 
Clinical description: ischemic rest pain (requires typical symptoms + ischemia grade 3); no wound. 
1 Small, shallow ulcer on distal leg or foot; no 
exposed bone, unless limited to distal phalanx 
No gangrene 
Clinical description: minor tissue loss. Salvageable with simple digital amputation (1 or 2 digits) or skin 
coverage. 
2 Deeper ulcer with exposed bone, joint or 
tendon; generally, not involving the heel; 
shallow heel ulcer, without calcaneal 
involvement 
Gangrenous changes limited to digits 
Clinical description: major tissue loss salvageable with multiple (≥3) digital amputations or standard 
TMA ± skin coverage. 
3 Extensive, deep ulcer involving forefoot and/or 
midfoot; deep, full thickness heel ulcer ± 
calcaneal involvement 
Extensive gangrene involving forefoot and 
/or midfoot; full thickness heel necrosis ± 
calcaneal involvement 
Clinical description: extensive tissue loss salvageable only with a complex foot reconstruction 
(nontraditional transmetatarsal, Chopart, or Lisfranc amputation); flap coverage or complex wound 




Table 3.3. Ischemia grading in WIfI  
Grade ABI Ankle systolic pressure TP, TcPO2 
0 ≥ 0.80 > 100 mm Hg ≥ 60 mm Hg 
1 0.6-0.79 70-100 mm Hg 40-59 mm Hg 
2 0.4-0.59 50-70 mm Hg 30-39 mm Hg 
3 ≤ 0.39 < 50 mm Hg < 30 mm Hg 
 
ABI, Ankle-brachial index; PVR, pulse volume recording; SPP, skin perfusion pressure; TP, toe pressure; 
TcPO2, transcutaneous oximetry.  
 
Flat or minimally pulsatile forefoot PVR = grade 3. Measure TP or TcPO2 if ABI incompressible (> 1.3). Patients 
with diabetes should have TP measurements. If arterial calcification precludes reliable ABI or TP measurements, 
ischemia should be documented by TcPO2, SPP, or PVR. If TP and ABI measurements result in different grades, TP 





































Table 3.4. Foot infection grading in WIfI  
Clinical manifestation of infection SVS IDSA/PEDIS 
infection 
severity 
No symptoms or signs of infection 0 Uninfected 
Infection present, as defined by the presence of at least two of the following 
items: 
 
 • Local swelling or induration 
 • Erythema > 0.5 to ≤ 2 cm around the ulcer 
 • Local tenderness or pain 
 • Local warmth 
 • Purulent discharge (thick, opaque to white, or sanguineous secretion) 
_________________________________________________________ 
Local infection involving only the skin and the subcutaneous tissue (without 
involvement of deeper tissues and without systemic signs as described below). 
 
Exclude other causes of an inflammatory response of the skin (eg, trauma, 
gout, acute Charcot neuro-osteoarthropathy, fracture, thrombosis, venous 
stasis). 
1 Mild 
Local infection (as described above) with erythema > 2 cm, or involving 
structures deeper than skin and subcutaneous tissues (eg, abscess, 
osteomyelitis, septic arthritis, fasciitis) and no systemic inflammatory 
response signs (as described below). 
2 Moderate 
Local infection (as described above) with the signs of SIRS, as manifested by 
two or more of the following: 
 
• Temperature > 38° or < 36°C 
• Heart rate > 90 beats/min 
• Respiratory rate > 20 breaths/min or PaCO2 < 32 mm Hg 




PACO2, Partial pressure of arterial carbon dioxide; SIRS, systemic inflammatory response syndrome 
a Ischemia may complicate and increase the severity of any infection. Systemic infection may sometimes manifest 
with other clinical findings, such as hypotension, confusion, vomiting, or evidence of metabolic disturbances, such 





Table 3.5. Clinical stages of major limb amputation risk based on WIfI classification 
Risk of amputation Proposed clinical stages WIfI spectrum score 
Very low  Stage 1 W0 I0 fI0,1 
  W0 I1 fI0 
  W1 I0 fI0,1 
  W1 I1 fI 0 
Low  Stage 2 W0 I0 fI2 
  W0 I1 fI1 
  W0 I2 fI0,1 
  Wo I3 fI0 
  W1 I0 fI2 
  W1 I1 fI1 
  W1 I2 fi0 
  W2 I0 fI0/1 
Moderate Stage 3 W0 I0 fI3 
  W0 I2 fI1,2 
  W0 I3 fI1,2 
  W1 I0 fI3 
  W1 I1 fI2 
  W1 I2 fI1 
  W1 I3 fI0,1 
  W2 I0 fI2 
  W2 I 1 fI0,1 
  W2 I2 fi0 
  W3 I0 fi0,1 
High Stage 4 W0 I1,2,3 fI3 
  W1 I1 fI3 
  W1 I2,3 fI2,3 
  W2 I0 fi3 
  W2 I1 fI2,3 
  W2 I2 fi1,2,3 
  W2 I3 fI0,1,2,3 
  W3 I0 fI2,3 
  W3 I1,2,3 fI0,1,2,3 
 
Clinical descriptors: 
Stage 1: Minimal ischemia; no/minor tissue loss 
Stages 2-4 reflect increasing stages of ischemia, wound, and infection 






Table 3.6. Comparison of different imaging modalities for patients with CLTI 
  







• Quick, widely available 
worldwide 
 
• Useful to monitor efficacy of 
therapeutic intervention 
• Highly operator dependent 
 
• Limitations to the visualization of iliac 
arteries due to body habitus, bowel gas 
 
• Calcification may produce incomplete 
examination 
 
• Most DUS studies were performed in mixed 
populations, thus, the validity of DUS 





Excellent patient acceptance 
 
• Ability to evaluate previously stented 
arteries 
 
• Mostly applicable in patients with 
contraindications for MRA 
• Image interference from calcified arteries 
 
 
• Potentially nephrotoxic contrast agents 
 
• Radiation exposure 
 
• Less reliable for imaging infrapopliteal 
vessels 
 
• Patients with CLTI who require a complete 
assessment of their lower extremity 
(including foot) arteries for planning a 
revascularization are under-represented in the 
current studies. The clinical value of CTA in 
the CLTI target population remains uncertain 
MRA • Non-invasive 
 
• Eliminates exposure to ionizing 
radiation 
 
• Unaffected by arterial calcification 
 
• Three-dimensional images of the 
entire arterial tree are presented in a 
maximum intensity projection 
format produced on a workstation 
 
• Easily produced arterial map aids 
planning of revascularization 
strategies 
• Patients with pacemakers and defibrillators 
and some cerebral clips cannot be scanned 
safely 
 
• Tendency to overestimate stenosis 
 
• Metal clips can cause artefacts that mimic 
vessel occlusions 
 
• Venous contamination can obscure arteries 




• Provides a complete map of the 
lower limb arteries 
 
• Images are easily displayed and 
interpreted by most physicians in 
charge of patients with CLTI 
 
• Selective catheter placement during 
lower extremity angiography 
enhances imaging, reduces contrast 
dose and enhances sensitivity in 
patients with CLTI 
• Exposure to ionizing radiation and contrast 
media 
 
• Alternatively, carbon dioxide and magnetic 
resonance contrast agents (eg, gadolinium) 
can be used instead of conventional contrast 
media 
 
• Complications of catheterization despite 









*The generic case of rest pain is used as a default for defining TAP as the least diseased IP artery, or a specific IP 




Restoration of in-line flow to the ankle and foot is a primary goal 
 
Target arterial path (TAP): the selected continuous route of in-line flow from groin to ankle. The 
TAP typically involves the least diseased infrapopliteal artery, but may be angiosome-based. 
 
Limb-based patency (LBP): maintained patency of the TAP. 
 
Inflow disease (aortoiliac and common femoral artery) is considered separately, and assumed corrected  
when using the infrainguinal staging system for clinical decision-making. 
 
Grade within segment is determined by presence of any one of the defined descriptors within that 
grade (ie, the worst disease attribute within the segment defines grade). 
 
Calcification considered only if severe; increases within segment grade by 1. 
 
Inframalleolar (IM) disease (pedal) modifier: describes status of IM vessels (including terminal 




Table 5.2. Inflow disease staging  
A simplified staging system for inflow (aortoiliac and CFA) disease is suggested. 
Hemodynamically significant disease (> 50% stenosis) of the CFA is considered a key modifier 
(A/B). 
I Stenosis of the common and/or external iliac artery, chronic total occlusion of 
either common or external iliac artery (not both), stenosis of the infrarenal 
aorta; any combination of the above. 
II Chronic total occlusion of the aorta; chronic total occlusion of common and 
external iliac arteries; severe diffuse disease and/or small caliber (< 6 mm) 
common and external iliac arteries; concomitant aneurysm disease; severe 
diffuse in-stent restenosis in the aortoiliac system. 








Table 5.5.3 Assignment of GLASS Stage. After selection of the TAP, the segmental FP and IP 
grades are determined from high-quality angiographic images. Using the table, the combination 
of FP and IP grades are assigned to GLASS Stages I-III, which correlate with technical 
complexity (low, intermediate, and high) of revascularization. 
 
 
    Infra-inguinal GLASS stage (I-III) 
FP Grade   
4 III III III III III 
3 II II II III III 
2 I II II II III 
1 I I II II III 
0 NA I I II III 
    0 1 2 3 4 











Table 5.6.4 Descriptive summary of GLASS stages of infra-inguinal arterial disease. 
 
 
PVI- peripheral [endo-]vascular intervention. LBP- limb-based patency.  
 Estimated PVI Outcomes  
STAGE Technical Failure 1-year LBP Anatomic pattern 
I <10% >70% Short-intermediate length FP disease and/or short length IP 
disease. No/minimal popliteal disease 
II <20% 50-70% Intermediate-long length FP disease, may include popliteal 
stenosis, and/or short-intermediate length IP disease.  
III >20% <50% Extensive FP or IP occlusions, alone or in combination with any 






Figure 5.1. Infra-malleolar/pedal disease descriptor in GLASS. Representative angiograms of P0 







Figure 5.2 Femoropopliteal disease grading in GLASS1 
 
 
1 Trifurcation is defined as the termination of the popliteal artery at the confluence of the AT and TP trunk 
 
 









Figure 5.4 Representative angiograms of GLASS Stage 1 disease patterns. The Target Artery 
Path (TAP) is outlined in yellow. 
Left panel. TAP includes the AT artery. FP grade is 0. IP grade is 2 (3 cm chronic total occlusion 
(chronic total occlusion of anterior tibial artery and total length of disease < 10 cm). 
Right panel. TAP includes the peroneal artery. FP grade is 2 (chronic total occlusion < 10 cm, 














Figure 5.5. Representative angiograms of GLASS Stage 2 disease patterns. The Target Artery 
Path (TAP) is outlined in yellow. 
Left panel. TAP includes the AT artery. FP grade is 1 (SFA occlusion < 5 cm). IP grade is 2 (two 
focal stenoses of anterior tiblial artery total length < 10 cm). 
Right panel. TAP includes the peroneal artery. FP grade is 0 (no significant stenosis). IP grade is 







Figure 5.6. Representative angiograms of GLASS Stage 3 disease patterns. The Target Artery 
Path (TAP) is outlined in yellow. 
Left panel. TAP includes the peroneal artery. FP grade is 4 (SFA disease length 10-20 cm, 
popliteal stenosis < 5 cm, heavily calcified). IP grade is 2 (stenosis of TP trunk and proximal 
peroneal < 10 cm). 
Right panel. TAP includes the AT artery. FP grade is 4 (popliteal chronic total occlusion 











TABLE 6.1: Comparison of risk stratification tools for the CLTI population 
  
 
Tool Endpoints Critical factors Reference 
Taylor et al Mortality, ambulatory 
failure (median follow up 2 
years) 
Age, race, ESRD, CAD, COPD, DM, 
dementia, baseline ambulatory status 
Taylor 2006 
405 
FINNVASC  Peri-operative (30 day) 
mortality, limb loss 
 









Survival (2 years) Age, CAD, smoking, tissue loss, BMI, 
Bollinger score, serum creatinine, ankle 
pressure (number measured and highest 




Peri-operative (30 day) 
mortality, morbidity 
Age > 75, prior 
amputation/revascularization, tissue 
loss, ESRD, recent MI/angina, 




Soga et al Survival (2 years) Age, BMI, non-ambulatory status, 
ESRD, cerebrovascular disease, tissue 
loss, left ventricular ejection fraction 
Soga 2014 225 
VQI AFS (1 year) Age, tissue loss, DM, CHF, serum 
creatinine, ambulatory status, urgent 
operation, weight, bypass conduit used 
Simons 2016 
67 
VQI Survival (30 day, 2 and 5 
years) 
Age, CKD, ambulatory status, CAD, 
CHF, COPD, tissue loss, diabetes, 




ESRD, end-stage renal disease; CAD, coronary artery disease; COPD, chronic obstructive 
pulmonary disease; DM, diabetes mellitus; AFS, amputation-free survival; BMI, body mass 











Figure 6.1. Paradigm for EBR in the treatment of CLTI. Patient risk, Limb severity, and 
























Figure 6.2. PLAN framework of clinical decision-making in CLTI; infrainguinal disease. Refer 
to Figure 6.4 for preferred revascularization strategy in standard risk patients with available vein 
conduit, based on limb stage at presentation and anatomic complexity. Approaches for patients 







Figure 6.3. The benefit of performing revascularization in CLTI increases with degree of 
ischemia, and with the severity of limb threat (WIfI Stage). WIfI Stage 1 limbs do not have 













Figure 6.4. Preferred initial revascularization strategy for infrainguinal disease, in average-risk 
patients with suitable autologous vein conduit available for bypass. Revascularization is 
considered rarely indicated in low limb-risk settings (WIfI Stage 1).  
Anatomic stage (y-axis) as determined by GLASS; limb risk (x-axis) as determined by WIfI 
staging. Dark grey shading indicates scenarios with least consensus. (Assumptions- inflow 



















Table 8.1. Major trials of gene therapy and cell therapy 
 
  
Trial Treatment Number of 
participants 
Endpoints Reference 
   AFS at 12 months 
(treated vs placebo) 
Other endpoints Treatment vs 
placebo 
 
Gene Therapy  
TALISMAN  FGF 125 73% vs 48% 
(P = 0.009) 




 FGF 525 63% vs 67% 
(P = 0.48) 
  Belch et al 
2011520 
HGF-STAT  HGF 104 No difference Change in 
TcPO2 at 6 
months 
25.2 mm Hg in 
high dose group vs 
9.4 mm Hg in 
placebo group 
(P = 0.0015) 
Powell et al 2008 
522 
HGF-0205  HGF 27 No difference Change in TBI 
at 6 months 
+0.05 vs -0.17 
(P = 0.047) 
Powell et al 2010 
521 
Shigematsu et al  HGF  40 No difference Improvement in 
rest pain or 
reduction in 
ulcer size 
70.4% vs 30.8% 
(P = 0.014) 
Shigematsu et al 
2010523 
Cell Therapy  
Iafrati et al  Autologous 
bone 
marrow  
97 No difference Improvement in 




TBI at 6 months 
58% vs 26% 
(P = 0.025) 
 
0.48 vs 0.012 
(P = 0.02) 
Iafrati et al 2011, 
2016524,526 
RESTORE-CLI  Expanded 
autologous 
stem cells 
72 No difference Combined 
outcomes 







40% vs 67% 
(P = 0.045) 
Powell et al 
2012528 




152 80% vs 69% 
(P = not 
significant) 
  Murphy et al 
2011, 2016524,527 
JUVENTUS  BMMNC 160 77% vs 84%  





19% vs 13% 






Table 9.1. Major Amputation of the Lower Extremity 
Level of 
Amputation 
Below Knee Through Knee Above Knee 
Primary 
Healing 








12% - 20% 1.5% - 20% 8% - 12% 








Table 11.1. IDEAL: stages of surgical and endovascular innovation for CLTI 
Stage 1 Idea 
2a 
Development 































































































Table 11.2. BASIL 2/3 and BEST-CLI trial endpoints 
Endpoints BASIL 2/3 BEST-CLI 
Primary AFS MALE-Free Survival 
Secondary Freedom from all-cause mortality 




Relief of ischemic pain 
Psychological morbidity 
HRQL: generic and disease-specific 
instruments 
Re- and cross-over intervention rates 
Healing of tissue loss (ulcers, 
gangrene) 
Extent and healing of minor 
amputations 
Hemodynamic changes; absolute ankle 
and toe pressures, ABI, TBPI 
HRQL (VascuQoL and EQ-5D) 
Health economic analysis 
Freedom from all-cause mortality 
RAFS 
Freedom from MALE + POD  
AFS 
Freedom from myocardial infarction 
(MI) 
Freedom from stroke 
Freedom from reinterventions (major and 
minor) in index leg 
Number of reinterventions (major and 
minor) per limb salvaged 
Freedom from hemodynamic failure 
Freedom from clinical failure 
Freedom from CLTI 
HRQL (VascuQoL and EQ-5D) 
Health economic analysis  
Abbreviations: MALE, major adverse limb event; MACE, major adverse cardiac event; HRQL, health-related 
quality of life; VascuQoL, vascular quality of life; ABI, ankle-brachial index; TBPI, toe-brachial pressure index; 






Table 12.1. The three tiers of care for amputation prevention/diabetic foot care centers 
 
Clinical Level of 
Care 
Setting Potential Clinicians Role 
 
Basic  
Model of Care 
 
General practitioner’s 















Model of Care 
 























Large teaching hospital, 





























Table 12.2. Criteria for Center of Excellence designation in CLTI or amputation prevention 
 
Center of Excellence Criteria Description 
Multidisciplinary team of specialists Specialists who can surgically and medically 
manage PAD and infections and provide the 
general or intensive medical care needed for 
the complex CLTI patient. 
Protocol-driven care A team that follows written, evidence-based 
clinical practice pathways, policies, and 
procedures. 
Outcomes monitoring and reporting Established a process for data collection and 
reports that data to the community or in the 
literature 
Methods of improvement Establishes a process for continual 
improvement based on outcomes and new 
techniques or therapies 
Educational resource Serves as an educational resource for the 
medical community via mentoring, 


















Table 12.3. The eight essential skills to prevent amputations in diabetes and the possible 
specialty responsible. 
 
Essential Skills Possible Team Members 
 
The ability to perform hemodynamic and 




 (cardiologist or radiologist) 
Vascular medicine 
 














The ability to perform wound assessment and 








The ability to perform site-specific bedside 








The ability to initiate and modify culture-









The ability to perform revascularization 
Vascular surgeon 
Interventionalist  
 (cardiologist or radiologist) 
 
The ability to perform soft tissue or osseous 






The ability to perform appropriate 
postoperative monitoring to reduce risks of 
reulceration and infection 
Podiatrist 
Wound nurse 





Table 12.4. Major outcome measures for CLTI and Amputation Prevention 
  
Quality Assurance Measure Calculation 
 
Limb salvage rate 
#of total Patients - # of major amputations (BKA or 
AKA) 
# of total patients 
 
 
Major to minor amputation ratio 
#of major amputations performed (BKA or AKA) 
#of limb-sparing amputations performed 
 
 
Healing percent – all wounds 
# of wounds healed 
total # of wounds – palliative care patients 
 
 
Healing percent – DFUs 
# of DFUs healed 
total # of DFUs – palliative care patients 
 
 
Median days to heal – all wounds 
Calculate days to heal for all wounds. Exclude 
amputated and palliative patients. 
 
 
Median days to heal – DFUs 
Calculate days to heal for all DFUs. Exclude 
amputated and palliative patients. 
 
Non-invasive vascular study – DFUs # of NIVS performed 
# of new DFU patients 
 
 
Revascularization success – open 
bypass 
# of open bypass patients - # open bypass failures 
# of open bypass patients 
 
 
Revascularization success - 
endovascular 
# of endovascular patients - # endovascular failures 
# of endovascular patients 
 
AKA = above-knee amputation, BKA = below-knee amputation, DFU = diabetic foot ulcer, NIVS = non-invasive 








Figure 12.1. The elevating risk of the “Stairway to an Amputation,” or the natural history of 
diabetes-related amputations. Adapted from Rogers LC and Armstrong DG. “Podiatry Care,” in 


































25-29 years 3.02 11.91 10.34 
30-34 years -1.52 7.62 5.82 
35-39 years -4.12 22.49 16.19 
40-44 years -3.28 32.05 22.59 
45-49 years 7.14 25.83 20.51 
50-54 years 12.15 42.40 32.37 
55-59 years 31.31 55.53 47.49 
60-64 years 16.85 29.90 25.06 
65-69 years 4.90 20.29 14.35 
70-74 years 8.02 29.73 20.05 
75-79 years 11.68 41.36 26.75 
80-84 years 51.98 45.77 48.92 
85-89 years 34.80 47.86 39.84 
≥90 years 37.22 58.82 44.09 
Total 13.08 28.67 23.51 
 
Table 13.1. Estimated number of people living with peripheral artery disease. Adapted from: 






Country/Year 1990 - 2000 2000 -2010 2010 + 
Benin NA NA 42 
Ethiopia 11.6 NA NA 
Ivory Coast NA NA 22% 
Malawi 15 NA NA 
Nigeria NA 54 52 
South Africa 10.2 8.2 30 
Sudan 10 NA NA 
Tanzania 12..5 21 26 
Uganda NA NA 39 
Zambia NA NA 41 
 
Table 13.2: Prevalence of PAD (%) in Diabetics. Adapted from manuscript Abbas ZG, 
Archibald LK. Recent International Development: Africa. Chapter 34, The Foot in Diabetes. 
Edited by: Boulton AJM, Cavanagh P,  Rayman G. 4thEdition, John Wiley & Sons Ltd, 
www.wiley.com ;2006;379-385). Updated by Dr. Abbas Z.G (Tanzania) with review of regional 






Table 13.3 Contributors/Acknowledgements: The authors and the Steering Committee of 
GVG appreciate and recognize the contribution of the following for providing survey responses 
for this chapter. 
Argentina Dr. Juan Esteban Paolini President, Argentine Association of 
Angiology and Cardiovascular 
Surgery, Caba 
Brazil Dr. Tulio Pinho Navarro Vascular and Endovascular Surgery, 
Belo Horizonte-MG 
China Dr. Jinsong Wang Vascular and Endovascular Surgery, 
Guangzhou, Guangdong 
Colombia Dr. Alberto Munoz Vascular and Endovascular Surgery, 
Bogota; Secretary General WFVS-
ALCVA (Latin American Society 
Vascular Surgery and Angiology) 
Costa Rica Dr. Roger Jiménez Juárez Vascular and Endovascular Surgery, 
San Jose 
Cuba Dr. Alejandro Hernandez 
Seara 
National Institute of Angiology and 
Vascular Surgery, Havana 
Ecuador Dr. Victor Hugo Jaramillo 
Vergara 
Chief of Vascular Surgery 
Departament, Hospital Carlos 
Andrade Marín, Quito 
El Salvador Dr. Andres Reynaldo 
Hernandez Morales 
Vascular départements Chairman,  
Institute Salvadorien del Seguro 
Social 
India Dr. Varinder Bedi Head of Department- Dep. Of 
Vascular & Endovascular Surgery, 
Sir Gangaram Hospital, New Delhi 
India Dr. P. C. Gupta Head of Department - Dep. Of 
Vascular & Endovascular Surgery, 
CARE Hospital, Hyderabad 
Japan Dr. Tetsuro Miyata Professor, Vascular and 




Malaysia Dr. Yew Pung Leong Vascular and Endovascular Surgeon, 
The Vascular Centre, Sunway 
Medical Centre, Kuala Lumpur 
Mexico Dr. José Antonio Muñoa 
Prado 
Vascular and Endovascular Surgery, 
Chiapa 
New Zealand Dr. Thodur Vasudevan Vascular Surgeon; Chair -Board of 
Vascular Surgery; Waikato Hospital, 
Hamilton 
Paraguay Dr. Agustin Saldivar Orrego President of Paraguayan Society of 
Angiology and Vascular Surgery 
Peru Dr. Fernando Batista Sanchez Vascular and Endovascular Surgery, 
Lima 
South Africa Dr. Martin Veller Dean, Faculty of Health Sciences, 
University of the Witwatersrand, 
Johannesburg 
Spain Dr. Melina Vega de Ceniga Senior consultant, Angiology and 
Vascular Surgery, Hospital de 
Galdakao-Usansolo, Bizkaia 
Sri Lanka Dr. Mandika Wijeyaratne Consultant Vascular Surgeon, 
Colombo 
Tanzania Dr. Zulfiqarali G. Abbas Consultant Physician, Dar es Salaam 
Chairman, Pan-African Diabetic Foot 
Study Group, 
Vice President, D-Foot International 
Uruguay Dr. Marcelo Diamant President of ALCVA (Asociasión 
Latinoamericana de Cirugía Vascular 
y Angiología); Vascular and 
Endovascular Surgeon 
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